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Abstract 
There are approximately 743 million individuals suffering from chronic periodontitis (PD) making it the 
sixth most prevalent condition worldwide. The affected adult population in the U.S. are nearly 64.7 million 
and the healthcare costs exceeds $14 billion. Recently, host response to pathogenic infection has been 
seen critical to the progression of PD and exhibit increase in various inflammatory markers. Marijuana is 
well known for its recreational usage and is a risk factor for periodontal disease, which is seen as a 
concern in society for its negative health consequences. However, many medical conditions can benefit 
from the pharmacological effects of cannabinoids. Plethora of evidence is available for the use of 
cannabinoids for the anti-inflammatory and immune modulating activity. The targets for therapeutic 
intervention include the cannabinoid type 1 and 2 receptors (CB1R and CB2R). The CB2 receptor is an 
attractive target in the endocannabinoid system (ECS), due to widespread expression in peripheral tissue, 
upregulated expression during inflammation and lacks adverse psychotropic effects associated with CB1 
receptor. The expression of cannabinoid receptors are present in periodontal tissues, and play a role in 
the physiological protection of tissues against excessive inflammation. Our lead compound SMM-189 is a 
CB2 inverse agonist, which exhibited anti-inflammatory properties in various primary cell lines. We aimed 
to address the anti-inflammatory properties seen with cannabinoid synthetic compounds SMM-189 (CB2 
selective inverse agonist), HU308 (CB2 selective agonist), and the endocannabinoid anandamide (AEA) in 
periodontal disease. Our primary investigation led us to evaluate the most potent stimuli for the study, 
from which IL-1β emerged as the most robust inducer of cytokine and chemokine responses. The study 
was further expanded to include the most prominent biomarkers associated with infection, inflammation 
and disease. We addressed the hypothesis that effective inhibition of IL-1β-stimulated primary human 
periodontal ligament fibroblasts (hPDLF’s) will be seen with SMM-189 and HU308 and AEA. The synthetic 
cannabinoids exhibit excellent profile as an anti-inflammatory agent, while the endocannabinoid AEA 
exhibits dualistic effects that exerted both anti-inflammatory and pro-inflammatory effects. Our study 
revealed that the most potent anti-inflammatory effects were seen with SMM-189, an inverse agonist. 
Suggesting that targeting the endocannabinoid system in chronic periodontitis by an inverse agonist may 
lead to the development of novel drug for periodontal therapy. The outcome from this study has provided 
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There are approximately 743 million individuals suffering from chronic 
periodontitis (PD) making it the sixth most prevalent condition worldwide. The affected 
adult population in the U.S. are nearly 64.7 million and the healthcare cost exceeds $14 
billion. Recently, host response to pathogenic infection has been seen critical to the 
progression of PD and exhibit increase in various inflammatory markers. Marijuana is 
well known for its recreational usage and is a risk factor for periodontal disease, which is 
seen as a concern in society for its negative health consequences. However, many 
medical conditions can benefit from the pharmacological effects of cannabinoids. 
Plethora of evidence is available for the use of cannabinoids for the anti-inflammatory 
and immune modulating activity. The targets for therapeutic intervention include the 
cannabinoid type 1 and 2 receptors (CB1R and CB2R). The CB2 receptor is an attractive 
target in the endocannabinoid system (ECS), due to widespread expression in peripheral 
tissue, upregulated expression during inflammation and lacks adverse psychotropic 
effects associated with CB1 receptor. The expression of cannabinoid receptors are present 
in periodontal tissues, and play a role in the physiological protection of tissues against 
excessive inflammation. Our lead compound SMM-189 is a CB2 inverse agonist, which 
exhibited anti-inflammatory properties in various primary cell lines. We aimed to address 
the anti-inflammatory properties seen with cannabinoid synthetic compounds SMM-189 
(CB2 selective inverse agonist), HU308 (CB2 selective agonist), and the 
endocannabinoid anandamide (AEA) in periodontal disease. Our primary investigation 
led us to evaluate the most potent stimuli for the study, from which IL-1β emerged as the 
most robust inducer of cytokine and chemokine responses. The study was further 
expanded to include the most prominent biomarkers associated with infection, 
inflammation and disease. We addressed the hypothesis that effective inhibition of IL-1β-
stimulated primary human periodontal ligament fibroblasts (hPDLFs) will be seen with 
SMM-189 and HU308 and AEA. The synthetic cannabinoids exhibit excellent profile as 
an anti-inflammatory agent, while the endocannabinoid AEA exhibits dualistic effects 
that exerted both anti-inflammatory and pro-inflammatory effects. Our study revealed 
that the most potent anti-inflammatory effects were seen with SMM-189, an inverse 
agonist. Suggesting that targeting the endocannabinoid system in chronic periodontitis by 
an inverse agonist may lead to the development of novel drug for periodontal therapy. 
The outcome from this study has provided hopes for the development of drugs that will 












 Periodontitis is one of the most prevalent inflammatory diseases in humans with 
more than half a billion individuals suffering worldwide. In 2010, 701 cases per 100,000 
were recorded and the number rises each year. Periodontitis is a multifactorial disease 
and its progression depends on many factors including genetics, environment, smoking, 
oral habits, and age. The disease is debilitating and many experience a decreased quality 
of life due to ineffective mastication, aesthetics, facial disfigurement, and speech 
difficulty. The conventional approaches to control the progression of the disease include 
local debridement with application of oral antimicrobials. However, depending on the 
patient compliance and severity of disease, many patients require surgical intervention. 
No curative pharmacological therapy is available to control the overactive inflammatory 
state and arrest the disease process. Therefore, in this study we provide evidence that 
targeting the endocannabinoid system is an excellent way to achieve reduction in chronic 
inflammation by means of regulating proinflammatory responses. Our drug, SMM-189, a 
CB2 selective inverse agonist, provides excellent anti-inflammatory effects and may lead 
to the development of potent clinically relevant drugs for the treatment of periodontitis 







TABLE OF CONTENTS 
 
CHAPTER 1. INTRODUCTION ................................................................................. 1 
Origins of Modern Day Discovery ............................................................................... 1 
History and Background of Cannabinoid Receptors ..................................................... 3 
Cannabinoid Receptor Type 1 (CB1) ....................................................................... 5 
Cannabinoid Receptor Type 2 (CB2) ....................................................................... 5 
G-Protein Receptor 18 (GPR18), a Putative Cannabinoid Receptor .......................... 6 
Putative Cannabinoid Receptor (GPR55) ................................................................. 7 
Putative Cannabinoid Receptor (GPR119) ............................................................... 7 
Cannabinoids and Inflammatory Disease ..................................................................... 8 
CB2 Receptor in Atherosclerosis ............................................................................. 8 
CB2 Receptor in Inflammatory Neuropathic Pain .................................................... 9 
CB2 Receptor in Autoimmune and Neurodegenerative Disorders .......................... 10 
CB2 Receptor in Bone Disorders ........................................................................... 11 
CB2 Receptor in Immune Cell Population during Inflammation ............................. 11 
CB2 Receptor Activation and Anti-Inflammatory Pathway Induction .................... 13 
Current Projects Overview......................................................................................... 15 
CHAPTER 2. CYTOKINE IL-6 AND CHEMOKINE MCP-1 LEVELS ARE 
REDUCED VIA CB2 RECEPTOR IN AN IN VITRO PERIODONTITIS 
MODEL ....................................................................................................................... 17 
Introduction to Periodontitis ...................................................................................... 17 
Rationale of Cannabinoid Therapy for Periodontal Inflammation .............................. 17 
The Potential of SMM-189 in Periodontitis ............................................................... 19 
Methods .................................................................................................................... 19 
Cell Culture of Primary Human Periodontal Ligament Fibroblasts ......................... 19 
Cytotoxicity Assay ................................................................................................ 19 
Determination of IL-6 and MCP-1 ......................................................................... 20 
Results ...................................................................................................................... 20 
Evaluation of hPDLFs Responses to P.g. LPS, IL-1β, and TNF-α .......................... 20 
Effects of CB2 Activation by Anandamide on LPS, IL-1β and TNF-α Induced 
IL-6 and MCP-1 Production in hPDLFs ................................................................. 22 
Effects of Synthetic CB2 Ligands SMM-189 and HU-308 on LPS, IL-1β and 
TNF-α Induced IL-6 and MCP-1 Production in hPDLFs ........................................ 22 
Discussion and Summary .......................................................................................... 28 
CHAPTER 3. THE DOWNREGULATION OF CYTOKINE IN AN IN VITRO 
PERIODONTITIS MODEL VIA CB2 RECEPTOR LIGANDS .............................. 32 
Study Overview ......................................................................................................... 32 
Cytokines .................................................................................................................. 32 
Methods .................................................................................................................... 33 
Cell Culture of Primary Human Periodontal Ligament Fibroblasts ......................... 33 
Cytotoxicity Assay ................................................................................................ 33 
Effects of IL-1β ± SMM-189, HU-308, and AEA on Cytokine .............................. 33 
 
viii 
Statistical Analysis ................................................................................................ 34 
Results ...................................................................................................................... 34 
IL-1β Induced hPDLF Cytokine Production ........................................................... 34 
Inhibition of IL-1β Induced Cytokine Production by AEA ..................................... 34 
Inhibition of IL-1β Induced Cytokine Production by Synthetic CB2 Ligands 
SMM189 and HU-308 ........................................................................................... 34 
Discussion and Summary .......................................................................................... 44 
Pro-Inflammatory Cytokines IL-6, IFNγ, IL-1β. and TNF-α .................................. 44 
Cytokines IL-13, IL-2, GM-CSF, and VEGF ......................................................... 45 
The Comparison of GCF and hPDLFs Responses .................................................. 46 
CHAPTER 4. THE DOWNREGULATION OF CHEMOKINES IN AN IN 
VITRO PERIODONTITIS MODEL VIA CB2 RECEPTOR LIGANDS ................. 47 
Chemokine Overview ................................................................................................ 47 
Methods .................................................................................................................... 47 
Cell Culture of Primary Human Periodontal Ligament Fibroblasts ......................... 47 
Cytotoxicity Assay ................................................................................................ 48 
Effect of IL-1β ± SMM-189, HU-308, AEA on Chemokines ................................. 48 
Statistical Analysis ................................................................................................ 48 
Results ...................................................................................................................... 48 
IL-1β Induced Chemokine Production in hPDLFs .................................................. 48 
IL-1β Induced Chemokine Production in hPDLFs and the Effects Exhibited by 
AEA ...................................................................................................................... 50 
IL-1β Induced Chemokine Production in hPDLFs and the Effects of CB2 
Synthetic CB2 Inverse Agonist SMM189 and Agonist HU308 .............................. 50 
Discussion and Summary .......................................................................................... 50 
Chemokines Eotaxin-1, Eotaxin-3, MIP-1α, MIP-1β, and IP-10 ............................. 60 
Chemokines TARC, IL-8, MCP-1, and MDC ........................................................ 61 
Conclusions for the Study .......................................................................................... 62 
CHAPTER 5. THE DOWNREGULATION OF LEUKOCYTE ADHESION 
AND VASCULOGENIC MARKERS IN AN IN VITRO PERIODONTITIS 
MODEL VIA CB2 RECEPTOR LIGANDS .............................................................. 63 
Study Overview ......................................................................................................... 63 
Cannabinoid Regulation of Angiogenesis and Vascular Injury ................................... 63 
Methods .................................................................................................................... 64 
Cell Culture of Primary Human Periodontal Ligament Fibroblasts ......................... 64 
Cytotoxicity Assay ................................................................................................ 64 
Determining the Effects of IL-1β ± SMM-189, HU-308, and AEA on Leukocyte 
Adhesion and Vascular Biomarkers ....................................................................... 64 
Statistical Analysis ................................................................................................ 65 
Results ...................................................................................................................... 65 
IL-1β Induced Angiogenic and Adhesion Biomarkers in hPDLFs .......................... 65 
Effects Exhibited by AEA on Expression of Angiogenesis and Adhesion 
Biomarkers in IL-1β-Stimulated hPDLFs ............................................................... 65 
 
ix 
Effects of SMM189 and HU308 on Expression of Angiogenesis and Adhesion 
Biomarkers in IL-1β-Stimulated hPDLFs ............................................................... 70 
Discussion and Summary .......................................................................................... 70 
The Roles of VEGF, ICAM-1, and VCAM-1 in Disease ........................................ 70 
Regulation of VEGF, ICAM-1, and VCAM-1 by Cannabinoids ............................. 71 
CHAPTER 6. DISCUSSION....................................................................................... 72 
Periodontitis Overview .............................................................................................. 72 
Therapeutic Approach ............................................................................................... 73 
Overview of Cannabinoids and Our Results ............................................................... 73 
Overview of CB Pathways ......................................................................................... 74 
Overview of CB2 Agonist Pathway ........................................................................... 75 
Overview of CB2 Inverse Agonist Pathway ............................................................... 77 
Conclusions ............................................................................................................... 78 
LIST OF REFERENCES ............................................................................................ 80 
APPENDIX.  PRELIMINARY ANTI-BACTERIAL ACTIVITY SEEN WITH 
SMM-189 ................................................................................................................... 104 









LIST OF FIGURES 
 
Figure 1-1. A Few Compound Components Isolated from Cannabis sativa .................... 2 
Figure 1-2. Endogenous and Synthetic Cannabinoids .................................................... 4 
Figure 1-3. General Signaling Pathway Associated with CB2 Activation..................... 14 
Figure 2-1. Effects of P.g. LPS on hPDLFs.................................................................. 21 
Figure 2-2. Metabolic Activity for P.g. LPS (1µg/ml), TNF-α (10ng/ml), IL-1β 
(1ng/ml) Stimulated hPDLFs .................................................................... 23 
Figure 2-3. Baseline Responses of hPDLFs to Stimulation with P.g. LPS (1µg/ml), 
TNF-α (10ng/ml), IL-1β (1ng/ml) for 24 hr ............................................... 24 
Figure 2-4. Time Course of IL-6 Expression in P.g. LPS (1µg/ml) Stimulated 
hPDLFs .................................................................................................... 25 
Figure 2-5. Measurement of Cytotoxicity of AEA, SMM-189, and HU308 on 
hPDLFs .................................................................................................... 26 
Figure 2-6. The Effects of AEA on P.g. LPS, TNF-α, IL-1β Stimulated Production of 
IL-6 (A) and MCP-1 (B) in hPDLFs .......................................................... 27 
Figure 2-7. The Effects of SMM-189 on P.g. LPS, TNF-α, IL-1β Stimulated 
Production of IL-6 (A) and MCP-1 (B) in hPDLFs ................................... 29 
Figure 2-8. The Effects of HU308 on P.g. LPS, TNF-α, IL-1β Stimulated Production 
of IL-6 (A) and MCP-1 (B) in hPDLFs .................................................... 30 
Figure 3-1. Baseline Responses of hPDLFs to Stimulation IL-1β (1ng/ml) for 24 hr ...... 35 
Figure 3-2. The Effects of IL-1β Stimulated hPDLFs on the Production of IFN-γ ........ 36 
Figure 3-3. The Effects of IL-1β Stimulated hPDLFs on the Production of IL-1β ........ 37 
Figure 3-4. The Effects of IL-1β Stimulated hPDLFs on the Production of IL-2 .......... 38 
Figure 3-5. The Effects of IL-1β Stimulated hPDLFs on the Production of IL-6 .......... 39 
Figure 3-6. The Effects of IL-1β Stimulated hPDLFs on the Production of IL-13 ........ 40 
Figure 3-7. The Effects of IL-1β Stimulated hPDLFs on the Production of TNF-α ...... 41 
Figure 3-8. The Effects of IL-1β Stimulated hPDLFs on the Production of GM-CSF ... 42 
Figure 3-9. The Effects of IL-1β Stimulated hPDLFs on the Production of VEGF ....... 43 
 
xi 
Figure 4-1. Chemokine Production by hPDLFs in Response to Stimulation with IL-1β 
(1ng/ml) for 24 hr ..................................................................................... 49 
Figure 4-2. The Effects of AEA, SMM-189, or HU308 on IL-1β Stimulated 
Production of Eotaxin-1 by hPDLFs ........................................................ 51 
Figure 4-3. The Effects of AEA, SMM-189, or HU308 on IL-1β Stimulated 
Production of Eotaxin-3 by hPDLFs .......................................................... 52 
Figure 4-4. The Effects of AEA, SMM-189, or HU308 on IL-1β Stimulated 
Production of IL-8 by hPDLFs .................................................................. 53 
Figure 4-5. The Effects of AEA, SMM-189, or HU308 on IL-1β Stimulated 
Production of IP-10 by hPDLFs ................................................................ 54 
Figure 4-6. The Effects of AEA, SMM-189, or HU308 on IL-1β Stimulated 
Production of MCP-1 by hPDLFs ............................................................. 55 
Figure 4-7. The Effects of AEA, SMM-189, or HU308 on IL-1β Stimulated 
Production of MDC by hPDLFs ................................................................ 56 
Figure 4-8. The Effects of AEA, SMM-189, or HU308 on IL-1β Stimulated 
Production of MIP-1α by hPDLFs ............................................................. 57 
Figure 4-9. The Effects of AEA, SMM-189, or HU308 on IL-1β Stimulated 
Production of MIP-1β by hPDLFs ............................................................. 58 
Figure 4-10. The Effects of AEA, SMM-189, or HU308 on IL-1β Stimulated 
Production of TARC by hPDLFs............................................................... 59 
Figure 5-1. Angiogenic and Vascular Injury Markers Production by hPDLFs in 
Response to Stimulation with IL-1β (1ng/ml) for 24 hr .............................. 66 
Figure 5-2. The Effects of AEA, SMM-189, or HU308 on IL-1β Stimulated 
Production of ICAM-1 by hPDLFs .......................................................... 67 
Figure 5-3. The Effects of AEA, SMM-189, or HU308 on IL-1β Stimulated 
Production of VCAM-1 by hPDLFs ......................................................... 68 
Figure 5-4. The Effects of AEA, SMM-189, or HU308 on IL-1β Stimulated 
Production of VEGF by hPDLFs ............................................................... 69 
Figure 6-1. Proposed Pathway for Signal Transduction by CB2 Agonist during 
Inflammation in hPDLFs .......................................................................... 76 
Figure 6-2. Proposed Pathway for Signal Transduction by CB2 Inverse Agonist 




LIST OF ABBREVIATIONS 
 
 
∆9-THC    (-)-trans-∆9-tetrahydrocannabinol  
2-AG     2-Arachidonylglycerol  
AbnCBD    Abnormal cannabidiol  
AC     Adenylyl cyclase  
AEA     Anandamide   
AjA     Ajumelic acid  
Alox5     Arachidonate 5-lipoxygenase  
ALS     Amyotrophic lateral sclerosis  
APC   Antigen presenting cell 
BDNF               Brain-derived neurotrophic factor  
bFGF    Basic fibroblast growth factor  
BMPs      Bone morphogenic proteins  
CB1     Cannabinoid receptor type 1 
CB2     Cannabinoid receptor type 2 
CBD     Cannabidiol  
CDC42    Cell division control protein 42 homolog  
CHD     Coronary heart disease  
CHO     Chinese hamster ovary cells 
CREB     cAMP response element-binding  
CRP     C - reactive protein  
ECP     Eosinophil cationic protein  
ECS     Endocannabinoid system  
Eotaxin-1 (CCL11)  Chemotactic for eosinophils 
Eotaxin-3 (CCL26)   Also known as macrophage inflammatory protein 4-alpha, 
ERK     Extracellular signal regulated kinase 
FAAH    Fatty acid amide hydrolase   
FBS     Fetal bovine serum  
FLS     Fibroblast like synoviocytes  
Flt-1     Fms-like tyrosine kinase  
GIP     Glucose-dependent insulinotropic peptide  
GLP-1    Glucagon-like peptide 1 
GM-CSF    Granulocyte-macrophage colony stimulating factor   
GPCR     G-protein coupled receptors  
GPR119    G-protein Receptor 119 
GPR18    G-protein Receptor 18 
GPR55    G-protein Receptor 55 
HCAECs    Human coronary artery endothelial cells  
HEK293    Human embryonic kidney cell line 
hGF     Human gingival fibroblasts  
hPDLCs    Human PDL cells  
hPDLFs    Human periodontal ligament fibroblasts  
HU308    (CB2 selective agonist) 
ICAM-1    Intracellular adhesion molecule 1  
 
xiii 
IFN-γ     Interferon-gamma   
IL-10     Interleukin-10  
IL-12/IL-23p40   Interleukin-12/ interleukin-23 p40 
IL-12p70    Interleukin-12 p70  
IL-13     Interleukin-13  
IL-15     Interleukin-15  
IL-16     Interleukin-16  
IL-17A    Interleukin-17A  
IL-1α    Interleukin-1alpha  
IL-1β      Interleukin-1 beta 
IL-2     Interleukin-2  
IL-4     Interleukin-4  
IL-5     Interleukin-5  
IL-6     Interleukin-6  
IL-7     Interleukin-7  
IL-8 (CXCL8)   Interleukin-8  
JNK     c-Jun N-terminal kinase  
LPS     Lipopolysaccharide  
MAPK    Mitogen activated protein kinases  
MCP-1    Monocyte chemoattractant protein 1  
MCSF    Macrophage colony stimulating factor  
MDC (CCL22)   Macrophage derived chemokine  
MDC     Macrophage derived-chemokine  
MGL     Monoacylglycerol lipase  
MIG     Monokine induced by IFNγ 
MIP-1α (CCL3)   Macrophage inflammatory protein 1-alpha  
MIP-1β (CCL4)   Macrophage inflammatory protein 1- beta  
MMP     Matrix metalloproteinase  
MS     Multiple sclerosis  
NAGly    N-arachidonoyl glycine 
NFAT     Nuclear factor of activated T-cells  
NF-κB    Nuclear factor kappa-light-chain-enhancer of activated B 
cells  
NO     Nitric oxide  
NSAID’s    Nonsteroidal anti-inflammatory drugs  
OEA     Oleoylethanolamide  
OLPC     Oleoyl-lysophosphatidylcholine  
OPG     Osteoprotegerin  
ORF     Open reading frame  
P.g.     Porphyromonas gingivalis  
PD     Periodontal disease  
PGE2     Prostaglandin E2  
PI-3K     Phosphatidylinositol 3-kinase  
PIGF     Placental growth factor  
PMNs     Polymorphonuclear neutrophils  
PTH     Parathyroid hormone  
 
xiv 
PYY     Polypeptide YY 
RA     Rheumatoid arthritis  
Rac1     Ras-related C3 botulinum toxin substrate 1  
RA-FLS    Rheumatoid arthritis-fibroblast like synoviocytes  
RANKL    Receptor activator of NF-kB ligand  
RhoA     Ras homolog gene family, member A  
ROCK    RhoA and Rho-associated, coiled-coil containing protein 
kinase  
SAA     Serum amyloid A  
SMM-189    (CB2 selective inverse agonist) 
TARC (CCL17)   Thymus and activation-regulated chemokine  
Th1     T-helper cell  
Th2     T-helper cells  
Tie-2    Tyrosine kinase-2  
TNF-α    Tumor Necrosis factor alpha  
TNF-β    Tumor Necrosis factor beta  
VCAM-1    Vascular cell adhesion molecule 1 







CHAPTER 1.    INTRODUCTION 
 
 
Origins of Modern Day Discovery 
 
The properties of the hemp (Cannabis sativa) is well documented for its use in 
textile manufacture and for its medicinal value [1]. The ancient world used cannabis as a 
therapeutic agent and its use is documented in Ayurvedic (Hindu/Indian) remedies for its 
analgesic, hypnotic, anti-spasmodic properties [2] that were also seen being used by the 
Chinese 2000 years ago for its anesthetic properties in surgery. The Persians were the 
first to have combination of cannabis and camphor given as an anesthetic, which was 
used as an alternative method of childbirth [3, 4]. Furthermore, medicinal uses of 
cannabis by Arabic-Islamic scientists and physicians to treat ear disease, skin disease, 
epilepsy, abscess, tumors, nociceptive, pyretic, parasitic, and emetic are still ahead of our 
current curative knowledge of hemp [5]. Hashish (derived from Cannabis) was used in 
the treatment of epilepsy for the Chamberlain of the Caliphate Council’s son in Baghdad, 
Zahir-ad-din, who was cured but had to use it for rest of his life. However, due to its side 
effects, many Islamic jurists banned it completely as it was believed to cause 
intoxication, uncivilized behavior, and also led to homosexuality [2, 6].   
 
The western world saw the use of Cannabis for its medicinal value and recreation 
usage much later. Much of 1800’s and early 1900’s the active ingredients in Cannabis 
were unknown. However, in early 1930s Cahn and coworkers agreed that the principle 
component of Cannabis has a high boiling point and was not an alkaloid. This work with 
Cannabis Indica, named due to its Indian origin, was used to isolate the oily product 
cannabinol [7] and provided a first observation of a compound. It was not till 1964, when 
(-)-trans-∆9-tetrahydrocannabinol (∆9-THC) (Figure 1-1.) was isolated by Gaoni and 
Mechoulam [8]. Subsequent studies led to animal models in which body temperature, 
catalepsy, and analgesia were examine to the extent that at least 6 components of 
Cannabis were considered pharmacologically effective [9]. Furthermore, motor activity 
was studied in rats, which led to compulsive behaviors such as forepaw threading, 
rhythmic jaw movement, prolonged head grooming and cage biting[10].  Severe motor 
disturbances were seen in dogs, while postural changes were seen in monkeys with 
∆9-THC. This study included more than one analogue of ∆9-THC and also examined 
other components of Cannabis for its pharmacological properties[11]. As early as the 
1970’s cannabis sativa grown in Pakistan was being used as a commercial tincture of 
cannabis that included ∆9-THC, cannabidiol (Figure 1-1.), cannabigerol (Figure 1-1.), 
cannabichromene (Figure 1-1.), cannabicyclol (Figure 1-1.), cannabinol (Figure 1-1.), 
cannabielsoin, cannabitriol and were being imported into Britain [12]. Around this time, 
the CYP system of drug-metabolizing enzymes were being extensively studied and 
∆9-THC and other plant cannabinoids were studied with considerable efforts in 
characterizing the pharmacokinetics and metabolic fate of these compounds [13]. It is 
generally accepted now that the metabolism and elimination of ∆9-THC is done by the 
hepatic CYP2A and CYP3C enzymes leading to the primary metabolite 11-hydroxy-
∆9-THC.  The metabolite retains its pharmacologically activity, while other minor 











discovery in the early days of cannabinoid research was the fact that the (-)-trans isomer 
elicited cannabinomimetic activity while the (+)-trans is inactive.  This lead to the 
hypothesis that a receptor was responsible in the biological activity and was not due to 
the high lipophilicity and perturbation of the cell membrane. The conclusive evidence of 
a cannabinoid receptor was discovered by two in vitro bioassays. One measured the 
adenylate cyclase activity [15], while the other was radioligand binding assays[16, 17]. 
These results led to cloning and subsequent identification of endogenous ligands. 
 
 
History and Background of Cannabinoid Receptors 
 
Initially it was believed that pharmacological effects attributed to the highly 
lipophilic compounds in Cannabis behaved similar to general anesthetics and was caused 
by disorder in the lipid membranes [18]. In studies later, stereospecific activity was seen 
in several cannabinoids[19], which led Devane and coworkers in 1988 [20] to utilized a 
highly selective tritiated Pfizer compound [3H]-CP 55,940 (Figure 1-2.) in the brain and 
neuronal cells of rat brain. This study provided evidence for the presence that a specific 
cannabinoid receptor in the rat brain. Confirmation came when the isolation of the cDNA 
for this receptor was performed and transfected in Chinese hamster ovary (CHO) cells, 
which was named the cannabinoid receptor type 1 (CB1) [21]. After the identification of 
the CB1 receptor, Munro and coworkers in 1993 isolated and cloned second cannabinoid 
receptor subtype, cannabinoid receptor type 2 (CB2) in human pro-myelocytic cell line 
HL60 [22]. The cannabinoid receptors belong to the superfamily of G-protein coupled 
receptors (GPCRs) that have seven transmembrane alpha helices with a glycosylated N-
terminus and intracellular C-terminus [23]. Furthermore, amino terminal spliced mRNA 
variant of CB1 has been reported and is named CB1A[24]. The CB1 receptor is highly 
conserved and has been cloned from mouse, rat, and human tissue and exhibits 97-99% 
amino acid sequence identity within these species. The CB2 receptor exhibits 48% 
homology with the CB1 cannabinoid receptor [23] and a comparison of the CB2 receptor 
within species revealed that mouse and rat CB2 receptors share 90% nucleic acid and 
93% amino acid identity, while rat and humans CB2 receptors share 81% nucleic acid 
and amino acid identity. Due to the differences within species, different binding affinities 
for ligands such as WIN-55212-2 (Figure 1-2.) have been found [25]. Two 
endocannabinoids have been studied extensively for their activity at the CB1 and CB2 
receptors. Anandamide (AEA) (Figure 1-2.), which activates the CB1 signal transduction 
with low efficacy [26] and at CB2 behaves as a partial agonist or antagonist [25, 27-29]. 
The second endocannabinoid, 2-arachidonylglycerol (2-AG) (Figure 1-2.) is a full 
agonist at both CB1 [30] and CB2 [27] receptors. The endocannabinoids are rapidly 
metabolized by enzyme fatty acid amide hydrolase (FAAH) [31].  In addition, 2-AG can 
be metabolized by two pathways one is via monoacylglycerol lipase (MGL) [32, 33], or it 
isomerizes to an inactive compound 1(3)-arachidonylglycerol [34, 35]. Other orphan 
receptors have also been categorized as putative cannabinoid receptors such as GPR18 
[36], GPR55 [37-39] and GPR119 [40]. These receptors have been proposed based on 
GTPγS binding studies in brain membranes prepared from CB1−/− mice. AEA and WIN-
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these knockout mice [41, 42], meanwhile Δ9-THC did not bind in CB1−/− mice, but was 
still able to induced analgesia, which might be due to other proteins or ion channels[43]. 
[44-46]. This complex pharmacology associated with cannabinoids can lead to additional 
difficulties especially when considering different tissues and/or organ systems. 
 
 
Cannabinoid Receptor Type 1 (CB1) 
 
The CB1 receptor is ubiquitously expressed throughout the body but is primarily 
found in the CNS [47].  The CB1 receptor is 52.8 kDa, a polypeptide with 472 amino 
acids, that couples to inhibitory Gi/o proteins [48], which causes the inhibition of adenylyl 
cyclase activity that leads to reduction in cAMP levels. However, under specific 
environmental conditions Gs coupling can occur thus stimulating cyclic AMP production 
[49]. CB1 receptors are involved with the regulation of many plasma membrane proteins, 
enzymes, modulation of cAMP, which leads to multiple signal transduction pathways, 
and ion channels. For instance, CB1 activation leads to the activation of voltage-sensitive 
outwardly rectifying K+ channels [50], inwardly rectifying K+ channels [51] and 
inhibition of voltage gated N, L, P and Q-type Ca+2 channels[52]. Therefore, activation of 
presynaptic CB1 receptors would cause the inhibition N-type calcium channels and 
reduce synaptic transmission, which is the underlying mechanism that is linked to THC 
induced psychoactive effects [52]. Furthermore, in the hippocampus, these presynaptic 
calcium channels on axonal terminus synapse on pyramidal neurons inhibit long-term 
potentiation are the probable cause of altered learning and memory [53-56]. The cellular 
effects of calcium channels activation by the CB1 receptors are associated with the signal 
transduction pathways mediated through mitogen activated protein kinases (MAPK) such 
as extracellular signal regulated kinase (ERK)[57, 58], c-Jun N-terminal kinase (JNK) 
[59, 60], p38 [61]. These kinases are involved with downstream regulation of various 
genes and have been shown to activate immediate early genes like c-Fos and Egr1 (Krox-
24) [62]. The neuroprotection of striatic cells from excitotoxic death is mediated via CB1 
receptor to activate the phosphatidylinositol 3-kinase (PI-3K)/Akt/mTORC pathway and 
induce brain-derived neurotrophic factor (BDNF) expression [63]. In addition to the 
MAPK activity, evidence suggests CB1 receptors stimulation leads to sphingomyelin 
hydrolysis which was seen with an increase in intracellular ceramide levels [64]. The 
ceramide pathway was further characterize by the use of THC in human glioma cells as 
the proposed mechanism of THC-induced cell death [65].  Additionally, 
endocannabinoids activate CB receptors on the presynaptic terminus to inhibit 
neurotransmitter release.  However, the signaling complexities in CB1 mediated 
transduction pathways, regulation via β-arrestin [66], formation of oligomers, 
homo/heterodimers [67, 68] can lead to varied pharmacological properties that are likely 
tissue and organ specific. 
 
 
Cannabinoid Receptor Type 2 (CB2) 
 
The CB2 receptor is generally characterized as the peripheral cannabinoid 
receptor and was initially presumed to be absent from the CNS [69]. However, recent 
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data suggests that CB2 is also found in the CNS especially in microglia [70, 71], blood 
vessels [72], and neurons [73, 74]. The CB2 receptor is predominantly found on the 
immune cells and couples to the inhibitory Gi/o proteins [75] that bind to its third 
intracellular loop and C-terminus. It is a 55 kDa protein [76] with 360 amino acid 
polypeptides [25], which is shorter and not as well conserved compared to CB1. CB2 
receptors inhibit adenylyl cyclase (AC), which leads to the decreased levels of cAMP and 
poorly modulates Ca2+ ion channel activity [77]. It has been reported that the content of 
CB2 mRNA is present in spleen and tonsils in levels comparable to the CB1 mRNA 
content in the CNS. Almost, all peripheral and blood immune cells express the CB2 
receptor with the following rank order with respect to mRNA levels: B cells>NK 
cells>monocytes>PMNs>T cells [78, 79]. The prevalence of CB2 receptor in the immune 
system suggests it plays an important role in immune function, which is supported by the 
observation of natural and synthetic cannabinoids exhibit immune-suppressive effects on 
various immune cells [80]. Nitric oxide synthase modulatory activity also is reported to 
be regulated by CB2 thus affecting the production of nitric oxide and reactive oxygens 
species which are important in immune response to invading pathogens [81, 82]. 
Macrophages, which play a major role in immune response can locally synthesize 
endocannabinoids AEA and 2-AG and exhibit higher CB2 receptors expression compared 
to CB1 receptors [78, 83]. In J774 macrophages, AEA inhibited the release of the LPS-
induced IL-6 and prostaglandin E2 (PGE2) release, that was most likely mediated via 
CB2 receptor [84, 85]. Additionally, CB2 receptor is involved with the regulation of bone 
homeostasis by controlling the osteogenic and osteoclastic gene expression.  The 
activation of the CB2 receptor stimulates MC3T3 E1 osteoblastic cells and mouse 
calvarial osteoblastic cultures [86]. Furthermore, CB2 receptor can serve as an excellent 
target to manipulate the inflammatory response and several studies have found an 
increase in CB2 receptor expression for disease states such as rheumatoid arthritis (RA) 
and Parkinson’s disease [80, 87-90]. The upregulation of CB2 receptor under 




G-Protein Receptor 18 (GPR18), a Putative Cannabinoid Receptor 
 
GPR18 is a seven transmembrane GPCR that shares greatest nucleotide sequence 
homology with rat mu opioid receptor with 34% amino acid similarity in the open 
reading frame (ORF). Radioligand binding studies with [3H]-bremazocine and [3H]-
diprenorphine however did not show any specific binding to the receptor. Interestingly, 
GPR18 had robust transcript levels in human testes and spleen, thymus, peripheral blood 
leukocytes, and small intestine, suggesting a role in immune-modulation [91]. In Chinese 
hamster ovary (CHO-K1) and myelogenous leukemia K562 stability transfected with 
GPR18 identified N-arachidonoyl glycine (NAGly) (Figure 1-2.) as target which 
significantly induced Ca2+ fluxes [92]. NAGly has similar structure to endogenous 
cannabinoids AEA and 2-AG, but exhibits no affinity to either CB1 or CB2 receptors [93, 
94]. However, stably transfected human embryonic kidney (HEK293) with hGPR18 
stimulated by NAGly, abnormal cannabidiol (AbnCBD) (Figure 1-2.), Δ9-THC, and 
AEA [36, 95] resulted in activation of ERK. The upregulation of GPR18 mRNA in 
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activated macrophages suggests that NAGly, and by extension cannabinoids, might play 
an important role in the functions of macrophages [96].  However, effectors of Gα(i/o)-
coupled receptors, adenylate cyclase, inwardly rectifying potassium channels in more 
recent studies have not been able to elicit ligand based signaling responses by GPR18 
signaling [97, 98].  
 
 
Putative Cannabinoid Receptor (GPR55) 
 
The GPR55 receptor is GPCR that couples to Gα12 and Gα13 identified and cloned 
by O’Dowd in 1999 [99, 100]. The activation of the GPR55 receptor leads to stimulation 
of a number of GTPases, such as Ras homolog gene family, member A (RhoA), Ras-
related C3 botulinum toxin substrate 1 (rac1), and cell division control protein 42 
homolog (cdc42) [37], which regulates variety of cellular events that are involved in cell 
growth, cytoskeletal reorganization, and the activation of protein kinases[101].  GPR55 is 
expressed in the brain, especially in the cerebellum, gastrointestinal tract in the jejunum, 
ileum and adrenal glands, while it’s not highly expressed elsewhere in the peripheral 
system [39]. Cannabinoids ligands such as CP-55,940, endocannabinoids AEA, 2-AG as 
well as phytocannabinoids Δ9-THC and cannabidiol (CBD) [39] bind to GPR55. GPR55 
activation leads to the induction of intracellular calcium release that activates 
transcription factors such as nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-κB), nuclear factor of activated T-cells (NFAT) and cAMP response element-
binding (CREB)[102]. The regulatory role of GPR55 upon stimulation can cause 
induction of F- actin formation mediate RhoA and Rho-associated, coiled-coil containing 
protein kinase (ROCK) [102] and osteoblast/osteoclast to modulate bone function [103]. 
To date, the physiological role of GPR55 is a mystery, but it has a potential role in the 




Putative Cannabinoid Receptor (GPR119) 
 
GRP119 is a GPCR that is found only in limited areas of the body. The expression 
is mostly limited to enteroendocrine cells in the intestine and β-cells in the pancreas. It 
increases insulin secretion and improves glucose control [108-110]. Therefore, its activity 
is involved in the homeostatic control of metabolism. GRP119 endogenous ligands such 
as Oleoylethanolamide (OEA), and Oleoyl-lysophosphatidylcholine (OLPC) are lipid 
molecules that signal via Gαs, thus activating causes an increase in AC activity and 
subsequent cAMP increase in GRP119 transfected HEK293 cells [111]. GPR119 has 
been seen in various vertebrate species and shares 96% amino acid identity between rat 
and murine, while human and mouse share 82% sequence identity [109]. Due to its 
lipophilic substrate profile and on the basis of homology clustering analysis, it is believed 
to be related with the cannabinoid receptors [112, 113]. The endocannabinoid AEA 
exhibited increased cAMP responses in GRP119 transfected cells that gave more 
evidence of it being related to the cannabinoid family [40]. GRP119 is being targeted as a 
mode of therapy for type 2 diabetes, which has shown improved glucose tolerance in 
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rodents and humans via oral administration. The underlying mechanism involves 
enhanced secretion of glucose-dependent insulin via β-cells and secretion of glucagon-
like peptide 1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and polypeptide 
YY (PYY) from the intestine[114].  
 
 
Cannabinoids and Inflammatory Disease 
 
Over the past decade, it has become clear that endocannabinoids and the CB 
receptors play a crucial role in the regulation of the immune response.  The 
endocannabinoid system is involved with infection and immune response that modulates 
variety of cells including T-cells, B-cells, the production of inflammatory cytokines, 
chemokines and affects cell migration [115-117].  The modulatory roles of CB2 in 
inflammatory diseases and pathological states have been demonstrated that include 
atherosclerosis, myocardial infarction, stroke, inflammatory pain, autoimmune disease, 
neurodegenerative disorder, fibrosis, bone disease, kidney disease, hepatic ischemia and 
receptor[80]  Targeting the CB2 receptor in particular is very attractive as it’s expression 
is widespread in peripheral tissue [118], the receptors are upregulated during 
inflammation [87-90], and lacks the adverse psychotropic effects associated with CB1 
receptor. For example, cannabinoids have been suggested for patients with asthma due to 
their regulation of airway response and bronchodilation [119-121]. In allergy induced 
airway diseases, cannabinoids resulted in a decreased allergen induced mucus production 
[122]. On the other end of the spectrum, inflammation plays a pivotal role in cancer 
formation for which it is estimated that approximately 25% of all cancer cases worldwide 
are triggered by infection and chronic inflammatory disease, [123, 124].  Multiple studies 
have indicated the therapeutic benefits of cannabinoids as anti-cancer agents by inhibition 
of tumor angiogenesis, induction of apoptosis and arresting the cell cycle in neoplastic 
cells [125-130]. Targeting CB2 receptors could potentially halt tumor development with 
fewer side effects and improve quality of life. Hence, the need for targeting CB2 receptor 
for inflammatory disease, which will provide new therapeutic approaches that translate to 
clinical treatment from bench side to bed side.  
 
 
CB2 Receptor in Atherosclerosis 
 
Heart disease is the major killer worldwide, while in the US in 2009, it accounted 
for 1 in 4 deaths with coronary heart disease (CHD) being the most common heart 
disease killing 370,0000 annually [131].  The major factor in heart disease is 
atherosclerosis in which the thickening and the hardening of the arteries is observed 
largely due to plaque buildup. This plaque is composed of cellular waste, cholesterol, 
fatty substances, fibrin and calcium deposits that has the potential to clog and block 
arteries, which lead to many pathological conditions. It has been reported that 
proinflammatory cytokines and even bacterial endotoxin mediate the development of 
atherosclerosis. The upregulation of a cytokine such as TNFα leads to the activation of 
nuclear factor kappa B (NF-kB) that affects adhesion molecules and chemokines to 
promotes active endothelial recruitment of monocytes [132]. The macrophages within 
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atherosclerotic lesions eats oxidized LDL that leads to the formation of foam cells and are 
involved in the progression of the disease [133]. The CB2 activation is associated with 
the interference of chemoattractant actions, which attenuated TNFα-induced Intracellular 
adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1(VCAM-1), monocyte 
chemoattractant protein 1 (MCP-1) in human coronary artery endothelial cells (HCAECs) 
[134]. Furthermore, ICAM-1, VCAM-1, and P-selectin expression was attenuated by 
CB2 activation and led to decreased macrophage adhesion and infiltration [135]. 
Interestingly, the modulation of the CB2 pathway also influences lesional macrophage 
apoptosis that is mediated by Akt survival pathways [133] and CB2 gene deletion exerted 
multiple complex effects that mediated atherogenesis and plaque stability [136].  The 
CB2 activity prevents the formation of plaque build-up, which provides a therapeutic 
opportunity for the preventive medicine in atherogenic heart disease. 
 
 
CB2 Receptor in Inflammatory Neuropathic Pain 
 
Effective interventions for neuropathic pain remains a big problem within patient 
populations and can be significantly resolved by cannabinoid based ligands.  For 
example, in carrageenan model for inflammation, rats were injected intraplantar to 
produce paw swelling. Administration of the CB2 selective agonist AM1241 suppressed 
hyperalgesia and allodynia, which were mediated by reduction of fos protein expression 
in carrageenan induced inflammatory model. The fos levels were decrease in superficial 
and neck region of the dorsal horn, but the nucleus proprius and ventral horn were 
unaffected.  The CB2 selective agonist AM1241 also produced normalization of 
nociceptive thresholds in inflammatory pain states [137]. In the capsaicin model, 
spontaneous pain alongside hypersensitivity of mechanical and thermal stimulation is 
observed [138], which was effectively suppressed by AM1241 in intradermal capsaicin 
injection to induce thermal hypersensitivity along with hyperalgesia and allodynia [139]. 
The CB2 selective agonist JWH-133 responded similarly to carrageenan induced 
inflammatory model by suppressing noxious mechanically evoked responses in wide 
dynamic range neuron response of rats [140]. Furthermore, JWH-133 was also able to 
reduce edema induced by carrageenan and the activity was comparable to systemic post-
administration of morphine and rofecoxib [141]. The formalin test is another well-
established model for pain, in which the pain is described to be biphasic. The initial or 
early phase of pain is described by the involvement of C and Aδ fibres, while later phase 
involves inflammation in the periphery [142]. CB2 agonists mediate formalin intraplantar 
injection nociception by mechanism that reduces the later phase associated with 
inflammation of the peripheral tissue [143, 144]. Furthermore, also worth mentioning, 
CB2 mRNA was found in spinal cord and dorsal root ganglia (DRG) in neuropathic rats 
and sham, while CB2 mRNA in microglia, which are implicated in neural development 
and maintenance [145] was also present in culture of spinal cord microglia [143].  Other 
animal models for neuropathic pain include ligating the L5 and L6 spinal nerves and 
partial sciatic nerve ligation [146].  The L5 and L6 spinal nerve ligation led to tactile and 
thermal hypersensitivity in rats that was reduced by AM1241 in a dose dependent manner 
[147]. This inhibition of pain was hypothesized to be outside the CNS and was seen by 
 
10 
release of beta-endorphins by keratinocytes that act on local neuronal mu-opioid 
receptors [148].  
 
 
CB2 Receptor in Autoimmune and Neurodegenerative Disorders 
 
Autoimmune disease is a consequence of immune dysfunction that leads to 
pathogenic mechanisms triggering attack of the host tissues. The progression to a chronic 
inflammatory state are due to genetic variants, environmental factors, infections that 
leads to destructive processes which involve self-antigens formation due to functional 
unresponsiveness of the immune response [149]. Rheumatoid arthritis (RA) is one of 
common autoimmune disorders that results in a joint deformity and loss of function with 
swelling, tenderness, and stiffness of the joints [150]. Ajumelic acid (AjA), an analog of 
THC is a potent anti-inflammatory and analgesic that exhibits reduced joint damage via 
oral administration in rats, while also inhibiting IL-1β production in primary human 
monocytes isolated from RA patients [151]. HU-320, another non-psychoactive synthetic 
compound similar to CBD had anti-inflammatory and immunosuppressive properties in 
murine collagen-induce arthritis. The study demonstrated that HU-320 protected mice 
from pathological damage induced by bovine collagen II. Furthermore, HU-302 decrease 
in serum levels of TNFα and the suppression in the production of TNFα from mouse 
macrophages and of reactive oxygen intermediates from RAW 264.7 cells [152]. IL-1β in 
cultured rheumatoid arthritis-fibroblast like synoviocytes (RA-FLS) increased the 
expression of CB2, and the agonist HU308 was effective in suppression of IL-1β -
induced proliferation of RA-FLS and production of IL-6, MMP3, MMP13 [88]. In many 
neurodegenerative disorders, cellular damage is seen with formation of free radical nitric 
oxide and superoxide anion, which lead to many different types of pathologies [153]. The 
production of free radicals leads to inflammatory response which is seen in multiple 
sclerosis (MS) patients.  Interestingly, CB2 was present in microglia and immune cells 
within MS plaques, which can play an important role in modulating the disease [154]. 
The overexpression of the CB2 receptor was abundant in Alzheimer’s disease brains and 
were selectively expressed in neuritic plaque-associated astrocytes and microglia [155]. 
CB2 agonists JWH-133, and WIN55,212 were neuroprotective as they prevented 
Alzheimer’s disease’s neurodegenerative processes via inactivation of microglial activity 
[156]. Cannabinoids can also play a potential role in Huntington’s disease, which is an 
autosomal dominant neurodegenerative disease that causes neuronal death and leads to 
impaired movements and cognition. In a rat model, CB2 receptor activation reduces the 
toxic levels of malonate produced in Huntington’s disease and causes the reduction of the 
proinflammatory response to protect the neurons [157]. In mouse models for amyotrophic 
lateral sclerosis (ALS), CB2 agonist AM1241 was effective in delayed disease state 
[158], while prolonging survival of the transgenic mice [159]. The activation of the CB2 
receptor mediated the responses of microglia and macrophages, which reduced their 
capability to induce proinflammatory components [160]. The experimental data strongly 
supports targeting the CB2 receptor as a promising approach to treating autoimmune and 






CB2 Receptor in Bone Disorders 
 
Bone modelling occurs throughout the course of one’s life via the actions of 
osteoblast (bone forming), and osteoclast (bone resorption) activity. However, an 
imbalance can occur due to age or other factors, which causes monocyte derived 
osteoclasts to have more rapid resorption rates and consequently followed by slower rate 
of bone formation by osteoblasts. These changes leads to osteoporosis that weaken the 
bone and increased risk of fracture[161, 162] Osteoporosis is associated with estrogen 
deficiency and females have an increased risk of developing bone disorders and 
degenerative diseases[163]. The underlying mechanism for bone control are primarily 
mediated by bone morphogenic proteins (BMPs) for osteoblasts, while osteoclasts are 
regulated via macrophage colony stimulating factor (MCSF), osteoprotegerin (OPG), 
interleukin-6 (IL-6) and receptor activator of NF-kB ligand (RANKL). The regulation of 
bone homeostasis is also affected by parathyroid hormone (PTH), calcitonin, leptin, 
insulin like growth factor I, and neuropeptide Y [161, 162]. It has been reported that both 
osteoblasts and osteoclasts and their precursors are involved in the synthesis of the 
endocannabinoids 2-AG and AEA [164]. Furthermore, mRNA transcripts reveal that CB1 
receptor is barely expressed by osteoclasts, while it abundantly expresses CB2 receptors. 
Meanwhile, the levels of CB2 receptors are expressed widely in both osteoclasts and 
osteoblasts [163, 165]. There have been some conflicting results with the activation of the 
CB2 receptor that has led to some confusion in field. It raised the question if CB2 
receptors actively play a role in bone formation or suppression. Mice deficient in CB2 
receptors resulted in low bone mass phenotype and CB2 agonist HU308 inhibited 
RANKL-induced osteoclast formation by direct stimulation of stromal cells such as 
osteoblasts and inhibition of pre-osteoclasts[165]. Conversely, endocannabinoids and 
CB2 agonists enhanced the effects of MCSF and RANKL-induced osteoclast formation 
[166]. Several other in vitro studies also found the stimulatory role of endocannabinoids 
at low concentrations and CB2 agonists polarized human osteoclasts to promote bone 
resorption [167, 168]. However, CB2 inverse agonists such as AM630 exhibited 
inhibitory effects on MCSF and RANKL-induced osteoclast formation [166, 168]. 
Moreover, CB2 deficient mice caused decreased production of osteoclasts in response to 
RANKL compared to wild type controls [169]. These studies indicate that CB2 receptor 
inverse agonist pharmacological action on osteoclast formation and reduction of bone 
loss in mice might be a viable option in treatment for osteoporosis [163]. However, the 
presence of contrary evidence makes the situation more complex and requires an in depth 
look at the experimental conditions. Nevertheless, the involvement of CB receptors and 
regulatory effects of the CB2 in bone strongly indicate the use of cannabinoids as 
antiresorptive drugs to treat osteoporosis and other types of bone disorders.   
 
 
CB2 Receptor in Immune Cell Population during Inflammation 
 
Peripheral and blood immune cells have abundant mRNA expression of the CB2 
that are involved in the modulation of the immune response [78, 79]. Upon an 
inflammatory stimulus, chemokines and cytokines are secreted from immune cells to 
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regulate the initiation and the resolution of inflammation. The disruption of immune 
responses can be seen during the dysregulation of cytokines that become active and 
perturb the balance between proinflammatory cytokines and anti-inflammatory cytokines. 
The cannabinoids have been shown to attenuate the proinflammatory mechanism that 
leads to decrease in chemokine and cytokine responses [170]. Moreover, the CB2 
selective ligands in peripheral blood monocytic cell line THP-1 cells decrease IL-1β and 
TNFα [171] and are devoid of the psychoactive activity associated with CB1 ligands. The 
CB2 agonist HU-308 attenuated liver damage in hepatic ischemia/reperfusion model by 
decreasing levels of TNFα, attenuation of leukocyte adhesion molecules ICAM-1 and 
VCAM-1, and a decrease in neutrophil infiltration [170]. The endocannabinoids also play 
an important role during inflammation and the increased local production of AEA by 
immune cells is thought to be a protective mechanism activated by the host during 
inflammation.  An increase in AEA is seen with LPS activated macrophages [172], and 
cannabinoids reduce the upregulation of NF-kB target genes TNFα and IL-6 by inhibiting 
NF-ĸB activation [173, 174]. CB2 agonists HU-308 and JWH-133 were efficient in 
suppression of TNF-α treatment of human coronary artery endothelial cells (HCAECs) 
that exhibited upregulation of MCP-1, ICAM-1 and VCAM-1 expression levels [134].  In 
chronic inflammation, IL-6 can be secreted by T-helper cells or macrophages to 
upregulate the inflammatory response which may regulate osteoclastogenesis and B-cell 
differentiation [175].  Stimulation of the B-cell line SKW 6.4 with IL-6 increased IgM 
levels and this upregulation was reduced by CB2 inverse agonist SR144528, whereas CB2 
agonist HU308 was ineffective [176]. Therefore, the role of CB2 inverse agonists have 
also been implicated in inflammatory models shown to be effective in vitro [177, 178] 
and in vivo [179].  
 
Macrophages are a major source of local inflammatory mediator and serve as an 
optimal therapeutic target as they are involved in promoting and resolving inflammation, 
wound healing, and host defense[180]. Resting macrophages and microglia undergo 
differential gene expression in response to many signals that drive the cells to an 
activated and responsive state. During activation they release various mediators such as 
nitric oxide (NO), TNFα, PGE2 and IL-6. Depending on the microenvironment presented 
to the macrophages, a phenotypic shift can be seen to a pro-inflammatory state M1 or a 
pro-wound healing state M2 [181, 182]. The shift of macrophage in M1 phenotype 
produces toxic nitric oxide, while the M2 state makes trophic polyamines [183]. During 
the occurrence of inflammation, macrophages undergo genetic transformation promoting 
upregulation of CB2 levels in activated cells [184]. This upregulation of CB2 receptors 
can be seen as an optimal target to modulate inflammatory responses. SMM-189, a CB2 
inverse agonist in microglia promoted a M2 state that mitigated adverse effects of mild 
traumatic injury, while also decreasing pro-inflammatory markers [185, 186]. 
Additionally, cannabinoids have also shown to affect macrophage functions by 
suppressing phagocytosis[187], bactericidal activity[187], inhibit synthesis of 
protein[188], alter cytokines[189-191]. Δ9-THC demonstrated impairment of 
immunological function in macrophage hybridoma, which functioned as an antigen-
presenting cell to secrete interleukin-2 (IL-2) upon stimulation of a soluble protein 
antigen-specific helper T cell hybridoma. It was suggested that Δ9-THC interfered with 
antigen processing instead of peptide presentation.  This is based on the observation that 
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IL-2 production was unaffected by Δ9-THC when the macrophages were presented with a 
synthetic peptide of the antigen to T cells [192]. Considering the central role of 
macrophages in many inflammatory conditions, targeting CB2 could serve to resolve 




CB2 Receptor Activation and Anti-Inflammatory Pathway Induction 
 
The ERK1/2 pathway is thought to be the primary mechanism for the signal 
transduction mediate via the CB2 activation that leads to the induction of growth related 
gene Krox-24. Signal transduction studies validated the mechanistic effects were 
mediated via CB2 by treatment with pertussis toxin, which ADP-ribosylates the αi 
subunit. To this effect, activation of CB2 led to an increase in cAMP instead of a 
decrease and prevented signaling of MAPK activity and Krox-24 induction [77, 193]. 
Many secondary messengers such as PKA, AKT, JAK/STAT1, CREB and ceramide have 
also been implicated in the signal transduction for CB2[194]. CB2 agonists demonstrate 
variable actions on MAPKs responsible for the activation of AP-1, leading to the increase 
in ERK1/2, but not activated JNK [193, 195]. However, in N9 murine microglial cells, 
activation of CB2 by the agonist JWH-015 without a stimulus led to an increase in 
ERK1/2 and JNK, but p38 was not affected. Microglia stimulated with LPS exhibited 
increased levels of ERK1/2, JNK, and p38 which was inhibited by CB2 agonist JWH-
015. This study also looked at knockdown of CB2 and TLR4 to establish that CB2 
agonist regulates ERK response independent of TLR4 signaling [196].  
 
Upregulation of CB2 was observed in rheumatoid arthritis fibroblast like 
synoviocytes (RA-FLS) and the activation of CB2 by HU-308 was responsible for the 
decrease in proinflammatory cytokines and matrix metalloproteinase (MMP) 3 and 13. 
The suppression of IL-1β induced activation of ERK1/2 and p38 MAPK in fibroblast like 
synoviocytes (FLS) was effectively inhibited [88]. In RA, the erosion and destruction of 
cartilage and invasiveness of the disease is associated with the MMP family [197]. 
Therefore, CB2 agonist may serve to protect the cartilage from damage in RA by 
inhibition of MMPs, which may be beneficial in oral inflammatory disease such as 
periodontitis, which exhibits similar pathology to RA. In T-cells activation of the CB2 
via an agonist JWH-015 transiently suppressed cAMP but prolong agonist exposure 
resulted in the increase of cAMP levels [198]. This response is intriguing as agonists can 
act via PI-3K/Akt and ERK1/2 signal transduction pathways, that initially led to 
chemoattractant activity in monocyte but the prolong exposure exhibited delayed effects 
resulting in inhibition of chemokine receptors CCR1 and CCR2 mRNA by PI-3K/Akt 
and ERK1/2 to cause reduction of chemotaxis [199]. In another study with human 
coronary artery endothelial cells (HCAECs) treated with TNF-a, synthetic CB2 selective 
agonists HU-308 and JWH-133 inhibited the upregulation of ICAM-1 and VCAM-1 
expression. The agonists also inhibited TNF-α-induced monocyte adhesion and MCP-1 
expression [134] (Figure 1-3). The possible mechanism involved for anti-inflammatory 





Figure 1-3. General Signaling Pathway Associated with CB2 Activation 
 
Orange arrows indicate CB2 mediated signaling, Blue arrows indicate other 
proinflammatory receptors signaling.  CB2 activation regulates adenylyl cyclase and 
decreases the cAMP response. In activated proinflammatory conditions, many receptors 
upregulated ERK, JNK, p38 for downstream signaling. This upregulation of ERK, JNK, 
p38 by external stimulus induction can be suppressed by activation of CB2R in respective 
cell types.  Prolong exposure of receptor ligand complex causes increase in cAMP and 
PKA either due to desensitization of the receptor or internalization.  PKA leads to 
attenuation of TCR response to decreases cytokine/chemokine production.  In non-
stimulated cells CB2 activation upregulates MAPK activity, especially ERK1/2 as 




attenuation in inflammatory response [200]. This is evidenced by the reports that 
activation of cAMP response element binding protein CREB leads to polarization of 
macrophages into an M2 anti-inflammatory pro-wound healing state [201, 202].  SMM-
189, a CB2 receptor inverse agonists also produced immune-modulatory effects by 
upregulating CD206, a marker for pro-wound healing, while decreasing the pro-
inflammatory marker CD16/32 [186]. Furthermore, SMM-189 significantly inhibited 
cytokine production while mitigated the adverse effects of mild traumatic brain injury 
[185, 186]. The NF-қB activation is considered the hallmark of pro- inflammatory 
responses and leukocytes recruitment [203] and this pathways is affected by cannabinoids 
via CB2 selective agonists JWH-133, HU308 [134] as well as CB2 selective inverse 
agonist such as SMM-189[185, 186], JTE-907, SR144528 [179]. There are many 
unanswered questions regarding the mechanism(s) wherein the ECS affects the diverse 
pathways involved in inflammatory cascades. What is emerging is that cellular signaling 
pathways are probably cell type specific and the CB1 and CB2 receptors are novel targets 
for therapeutic intervention [204]. 
 
 
Current Projects Overview 
 
The morbidity of chronic severe PD is affecting 743 million individuals 
worldwide, while millions of adults in the U.S. struggle with PD [205-207]. The affected 
hard and soft tissues surrounding the tooth [208] are the primary disease sites affected, 
which lead to compromised speech, mastication, and aesthetics. Several factors are 
involved for the initiation and progression of PD, but bacteria and its components are 
crucial in triggering the disease [208, 209]. However, the interactions exhibited by the 
host immune response dictate the severity of the disease. Therapeutic applications to 
control the active disease are antibacterial drugs which are not an optimal option to 
regulate inflammation (Appendix). Therefore, in this study our approach for therapeutic 
intervention was to decrease inflammation by containment of the inflammatory 
responses. There is a current unmet need in the field of periodontology for development 
of a novel compounds that treats the pathogenesis by reducing the inflammatory 
response.  
 
In this project, the work focused on developing and validating a model to study 
oral inflammatory disease such as PD. Publications from our laboratory and the plethora 
of literature provides evidence for the usage of cannabinoids for their ability to modulate 
inflammation. The CB2 receptor in particular is an attractive target in the 
endocannabinoid system (ECS), which lacks adverse psychotropic effects associated with 
CB1 receptor. Furthermore, it has widespread expression in peripheral tissue and its 
expression is upregulated during inflammation.  Earlier studies indicated SMM-189 to 
have potent anti-inflammatory activity on various primary cell lines. Therefore, we 
hypothesized that targeting the CB2 receptor would provide effective means as drug 
intervention to regulate the pro-inflammatory response underlying the progression of PD. 
To test the hypothesis the anti-inflammatory activities of synthetic cannabinoid ligands 
SMM-189 (CB2 selective inverse agonist), HU308 (CB2 selective agonist), and the 
endocannabinoid anandamide (AEA), were examined as well as the ligands respective 
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cytotoxicity in primary human periodontal ligament fibroblasts (hPDLFs). This was 
followed by optimization studies that included assay conditions, cytotoxicity, cell 
density, and optimal response of IL-6 and MCP-1 protein expression. After the model 
development and validation, the hPDLFs were stimulated via P. gingivalis (P.g.) LPS, 
recombinant human TNFα, or IL-1β to examine pro-inflammatory markers response of 
IL-6 and MCP-1 and the anti-inflammatory effects seen with the cannabinoid receptor 2 
ligands. Following our primary investigation, we identified IL-1β as the most robust 
inducer of IL-6 and MCP-1 responses compared to LPS and TNF-α (Chapter 2). The 
study provided the foundation for a detailed investigation of biomarkers associated with 
inflammation, infection and the progression of PD.  The biomarkers associated with PD, 
as well as many disease states, were broken down by Cytokines (Chapter 3), Chemokines 
(Chapter 4), Angiogenic and Vascular Injury Markers (Chapter 5). The studies revealed 
that the most potent anti-inflammatory effects were seen with SMM-189, an inverse 
agonist. The data strongly suggests that targeting the ECS and the CB2 receptor in 
chronic periodontitis by an inverse agonist may lead to the development of novel drug for 
periodontal therapy. The outcome from this study has provided hopes for the 






CHAPTER 2.    CYTOKINE IL-6 AND CHEMOKINE MCP-1 LEVELS ARE 
REDUCED VIA CB2 RECEPTOR IN AN IN VITRO PERIODONTITIS MODEL 
 
 
Introduction to Periodontitis 
 
Periodontitis (PD) afflicts approximately 64.7 million adults according to the 
Centers for Disease Control [205] and is one of the most common causes of tooth loss in 
adults. Worldwide, 743 million individuals are suffering from the chronic severe form of 
PD making it the 6th most prevalent condition worldwide. The healthcare cost in U.S. 
alone exceed over $14 billion [206, 210]. PD can be debilitating as it can decrease the 
quality of life due to alveolar ridge absorption, tooth loss, ineffective mastication, 
compromised aesthetics and speech difficulty. The chronic form of the PD is the most 
common and begins with the inflammation of gingiva (gingivitis) [211]. The 
conventional treatment for PD includes, scaling and root planing with local application of 
antimicrobial delivery [212]. In severe cases, surgical intervention and tissue grafts may 
be used to reduce the periodontal pocket which forms due to irreversible loss of the 
alveolar bone and the supportive tissues around the tooth. These treatments can be costly 
and require patient compliance (i.e. oral hygiene) and changes in certain habits (i.e. 
smoking). The pathogenesis of PD begins with bacterial accumulation on the hard and 
soft tissues surrounding the tooth [211]. The host response during periodontal infection 
activates proinflammatory responses that cause soft and hard tissue destruction. The 
destruction seen in PD is a consequence of disruption in the homeostatic balance that 
results in perpetual activation of the pro-inflammatory responses [213]. The complex 
network of cytokines is seen dysregulated and exaggerates the host responses that 
promotes inflammation. Attempts to reduce the bacterial load by the use of systemic 
antibiotics may improve the clinical parameters (bleeding) temporarily but lacks optimal 
dosage, duration, and efficacy against the spectrum of pathogens involved [208, 209], 
which can lead to increased rate of resistance [214]. The immunomodulation of the host 
responses could serve as a target for therapeutic intervention that could limit the damage 
seen from inflammation. 
 
 
Rationale of Cannabinoid Therapy for Periodontal Inflammation 
 
PD is a widely accepted risk factor for many systemic diseases, including 
cardiovascular disease, diabetes, rheumatoid arthritis and pre-term low weight babies 
[215-218]. The associated risk factors for PD and systemic disease might be due to loss 
of homeostatic balance between pro-inflammatory and anti-inflammatory responses that 
tipped the balance towards pro-inflammatory responses. Many inflammatory disease 
conditions increase the production of pro-inflammatory cytokines and chemokines. PD 
also has the dysregulation of cytokines and chemokines network that can cause 
interleukin-1 beta (IL-1β), interleukin-6 (IL-6), interleukin-8 (IL-8), and monocyte 
chemoattractant protein-1 (MCP-1) propagate the inflammation leading to bone 
resorption and destruction of periodontal tissue [219-223].  The dysregulated 
inflammatory process can be regulated by immunomodulation and is a prime target for 
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new therapeutic intervention in PD. Several approaches have been used in the past to 
limit the inflammation by steroids and Nonsteroidal anti-inflammatory drugs (NSAID’s). 
Long-term treatment with steroids demonstrated that standard of oral hygiene was the 
best measure for determining the severity of periodontal disease and no obvious influence 
on clinical parameters was seen with the use of corticosteroids [224]. NSAID’s 
administration has shown partial benefits including decreased gingival inflammation and 
shallower pocket depths [225], as well as decrease in bone loss during radiographic 
evaluation [226]. Even though these patients have seen favorable results taking NSAID’s 
for PD, NSAID use has serious adverse effects associated with kidney disease, 
gastrointestinal bleeds, increased blood pressure, and reduced wound healing [227]. 
Therefore, there is a current need for the development of novel anti-inflammatory agents 
to improve the quality of life and reduce treatment cost for those afflicted with PD.  
 
An emerging target for the development of novel anti-inflammatory and immune 
modulating agents is the endocannabinoid system (ECS) [115, 116, 228]. Cannabinoid 
(CB) receptors are ubiquitously expressed throughout the body. Cannabinoid type 1 
receptor (CB1) is primarily found in the CNS, while the cannabinoid type 2 receptor 
(CB2) is expressed on immune cells [21, 22, 229]. Nakajima et al. demonstrated that the 
endocannabinoid anandamide (AEA) and both CB1 and CB2 receptors are present in 
periodontal tissues, and are involved in the physiologic protection of tissues against 
excessive inflammation by regulating cellular pathways leading to anti-inflammatory 
responses [230]. The production of AEA also results in an increase in activated 
macrophages after exposure to LPS [172].  Additionally, CB receptors are upregulated in 
granulation tissue during healing [231].  Arguably the most promising target in the ECS 
is the CB2 receptor, due to its widespread expression in peripheral tissue [118] and the 
lack of adverse psychotropic effects associated with CB1 agonists. Many CB2 ligands 
exhibit immune-modulatory activity and are potent anti-inflammatory agents [115, 118, 
232].  The most extensively investigated CB2 ligands are agonists; however, CB2 inverse 
agonists have been gaining attention recently for their anti-inflammatory activities. For 
example, oral administration of the inverse agonists JTE-907 and SR144528 suppressed 
ear swelling comparable to steroid prednisolone and immune suppressant FK506 in a 
dinitrofluorobenzene (DNFB)-induced allergic dermatitis mouse model, without causing 
systemic immunosuppression [179].  
 
In an effort to further investigate the therapeutic potential of CB2 inverse 
agonists, our lab developed the selective CB2 inverse agonist SMM-189.  The therapeutic 
potential of SMM-189 as a new class of anti-inflammatory agents has been investigated 
in primary human microglia [186]. SMM-189 significantly inhibits the production of pro-
inflammatory cytokines interferon-gamma (IFN-γ), IL-6, interleukin-10 (IL-10) and 
interleukin-12 p70 (IL-12p70) and chemokines IL-8, MCP-1, macrophage inflammatory 
protein-1beta (MIP-1β), CCL17 (TARC), Macrophage derived-chemokine (MDC), and 
eotaxin-3 in activated microglia [185].  Furthermore, in C8B4, a murine microglia cell 
line, SMM-189 promoted the upregulation of CD206, which is a wound healing marker, 
while decreasing the pro-inflammatory marker CD16/32. Therefore, evidence suggests 
that CB2 receptor inverse agonists produce immune-modulatory effects by serving as 
anti-inflammatory agents, with the added benefit of promoting wound healing [186].  
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Moreover, SMM-189 mitigated in vivo the adverse effects of mild traumatic brain injury, 
including reversing deficits in motor function, fear retention, and loss of visual acuity 
[185]. The effect is in part due to shifting the activation state of microglia from M1, 
which is a prototypic proinflammatory phenotype to pro-wound healing M2 phenotype 
that antagonizes the proinflammatory M1 phenotype [185, 186].   
 
 
The Potential of SMM-189 in Periodontitis 
 
The cytokine and chemokine inhibition profile of SMM-189 is of considerable 
interest in PD since 1L-1β, tumor necrosis factor alpha TNF-α, IL-6, IL-8, MCP-1[233-
241] have been implicated in the initiation and progression of PD.  The bias of microglia 
to a pro-wound healing M2 state suggested an additional benefit of SMM-189 in PD.  
Activated macrophages are the peripheral equivalent of microglia and are implicated in 
the resolution of inflammation by phenotypic switch of M1 (proinflammatory) to a M2 
(pro-wound healing) state, thus mediating the periodontal tissue and alveolar bone 
destruction in PD [242, 243].  This led us to explore the effects of the CB2 inverse 
agonist SMM-189, as well as the CB2 selective agonist HU-308, and the 
endocannabinoid AEA for potential anti-inflammatory activity.  In this study, we used 
primary hPDLFs as a model, due to the role of these cells in amplification of the 
inflammatory state in PD [244].  We tested the effects of these CB2 ligands on PDL 
fibroblast production of IL-6 and MCP-1 in response to the pro-inflammatory mediators 
(IL-1β), (TNF-α), or lipopolysaccharide (LPS) from the periodontopathogen 






Cell Culture of Primary Human Periodontal Ligament Fibroblasts  
 
Primary human periodontal ligament fibroblasts (hPDLFs) were purchased from 
Lonza Walkersville, MD (CC-7049). Cell were cultured in the manufacturer’s 
recommended stromal cell basal medium (SCBM, CC-3204) with 5% fetal bovine serum 
(FBS) and SingleQuot Kit Supplements & Growth Factors (SCGM, CC-4181). The cells 
were taken from healthy individuals who were negative for HIV-I, Hepatitis B Virus and 
Hepatitis C Virus. Furthermore, these fibroblasts were validated via pan cytokeratin 
staining by Lonza. The cells had spindle-like shape and the experiments were performed 





Cells were plated in 96-well polystyrene flat bottom plates for the cytotoxic assay 
at cell densities of 10,000-20,000 cells/well. Cells were maintained in 5% FBS and 
SCGM Single Quot Kit Suppl. & Growth Factors media and 24 hr later the medium was 
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changed to SCBM basal medium containing 1% FBS, penicillin (100U/ml), and 
Streptomycin (100 µg/ml) (Mediatech, Inc. Manassas, VA) for another 24 hr at 37C, 5% 
CO2 to synchronize cell activity. Cytotoxicity for P. g LPS (Invivogen San Diego, CA) 
was tested at 10, 50, 100, and 1000 ng/ml, and human recombinant TNF-α and IL-1β 
(Invitrogen, Waltham MA) were used at 10ng/ml and 1ng/ml, respectively. SMM-189 
(synthesized in our lab), HU-308 (Tocris, Ellisville, MO) were prepared in DMSO and 
anandamide (Tocris, Ellisville, MO) in ethanol and were screened for cytotoxicity 
ranging from 10 -4 to 10 -6.5 M. Control groups were prepared with DMSO, ethanol and 
dH20 at the highest concentrations to which the cells were exposed. Cytotoxicity was 
assessed using the CCK-8 assay (Dojindo Molecular Technologies, Rockville, MD) by 
measuring the change in absorbance at 450 nm, using a BioTek Synergy 2 Multidetection 
Microplate Reader (BioTek Instruments, Inc. Winooski, VT). Data were analyzed using 




Determination of IL-6 and MCP-1 
 
To obtain PDL fibroblast-conditioned media for assays, cells were seeded at 
densities of 10,000-20,000 cells/well in 96-well polystyrene flat bottom plates. Medium 
was changed after 24 hr to SCGM basal medium containing 1% FBS, penicillin 
(100U/ml), and Streptomycin (100 µg/ml) for another 24 hr at 37°C, 5% CO2 to 
synchronize cell activity. P. gingivalis (P.g.) LPS, TNF-α, and/or IL-1β were added, an 
hour later SMM-189 (EC50 =13 µM), HU-308 (EC50 = 7.3µM), or AEA (EC50 =16 µM) 
were added. The conditioned medium was removed 24 hr later and assessed using 
Mesoscale Discovery Human Pro-Inflammatory IL-6 V-Plex kit (K151QXD) or Human 
Chemokine MCP-1 V-Plex Ultrasensitive kit (K151NNG). Plates were analyzed for 
levels of IL-6, MCP-1 according to manufacturer’s instructions using Mesoscale 
SECTOR 2400. All described values represent at least an average of three data points per 
determination. Data were analyzed using Graphpad Prism 6.0 using One-way ANOVA 






Evaluation of hPDLFs Responses to P.g. LPS, IL-1β, and TNF-α 
 
Inflammatory responses of hPDLFs were initiated by the stimuli LPS, IL-1β, and 
TNF-α but the responses can differ based on the origin of the hPDLFs cells [245-247]. To 
establish the response profiles for our hPDLFs, cells were exposed to IL-1β (1ng/ml) 
[245, 248] and/or TNF-α (10ng/ml) [249] or P.g. LPS.  The dose for P.g. LPS was 
determined via a cytotoxicity assay using increasing concentrations of P.g. LPS 10-1000 
ng/ml (Figure 2-1). No cytotoxicity was observed at any concentration thus the highest 






Figure 2-1. Effects of P.g. LPS on hPDLFs 
 
Cytotoxicity was measured using the CCK-8 assay after exposing cells to measure at 
concentration ranging from 1-1000ng/ml of P.g. LPS.  The data are presented as the mean 





of IL-1β at (1ng/ml) and TNF-α (10ng/ml), both of which did not exhibit any significant 
cytotoxic effects at the given concentrations. In fact, TNF-α exhibited a slight increase in 
its metabolic activity compared to control (p<0.05) (Figure 2-2). We used IL-6 and 
MCP-1 as proinflammatory markers which are strongly associated with inflammation and 
PD [230, 250-256]. To determine the protein expression levels of IL-6 and MCP-1, 
Mesoscale Discovery V-Plex plates were used. After 24 hr of treatment with 1µg/ml P.g. 
LPS a significant increases in IL-6 (p <0.05) (Figure 2-3) and MCP-1 (p<0.001) (Figure 
2-3) levels were seen compared to control.  However, P.g. LPS induced IL-6 counts in 
the lower detection limit of our assay’s linear range; therefore, we evaluated IL-6 
expression at 0, 6, 12, and 24 hr post treatment.  The study revealed that P.g. LPS is a 
weak stimulus of IL-6 in hPDLFs (Figure 2-4). Significant increases in the levels of IL-6 
(p<0.01) (Figure 2-3) and MCP-1 (p<0.0001) (Figure 2-3) were manifested 24 hr after 
stimulation with TNF-α. IL-1β exhibited a more robust and significantly higher increase 
for both IL-6 (p<0.0001) and MCP-1 (p<0.0001) (Figure 2-3) expression levels in 
comparison to P.g. LPS and TNF-α.  
 
 
Effects of CB2 Activation by Anandamide on LPS, IL-1β and TNF-α Induced IL-6 
and MCP-1 Production in hPDLFs 
 
AEA is produced endogenously by host cells and is believed to reduce the 
excessive production of pro-inflammatory molecules [250]. We therefore evaluated the 
effect of AEA in stimulated hPDLFs using an EC50 concentration of 16.0 µM determined 
in cytotoxicity assays (Figure 2-5). Cells were stimulated with P.g. LPS, TNF-α, and IL-
1β and 1 hour later AEA was added to the cultures. AEA alone elevated IL-6 (p<0.05) 
(Figure 2-6) levels compared to control and had no effect on MCP-1 expression (Figure 
2-6IL-6 levels were significantly decreased for AEA + TNF-α (p<0.05) and AEA + IL-1β 
(p<0.01) treatment groups compared to TNF-α, IL-1β alone, while P.g. LPS stimulated 
release of IL-6 was unaffected by AEA (Figure 2-6).  The chemotactic factor MCP-1 
was significantly reduced in all treatment groups with the greatest suppression manifest 
in the AEA + TNF-α (p<0.001) and AEA + IL-1β (p<0.001) groups compared to AEA + 
P.g. LPS (p<0.01) (Figure 2-6). 
 
 
Effects of Synthetic CB2 Ligands SMM-189 and HU-308 on LPS, IL-1β and TNF-α 
Induced IL-6 and MCP-1 Production in hPDLFs 
 
Synthetic CB2 ligands have demonstrated potential as novel anti-inflammatory 
agents thus we evaluated the selective CB2 inverse agonist SMM-189 and the selective 
CB2 agonist HU-308 at the EC50 concentrations 13µM and 7.3µM, respectively (Figure 
2-5). Interestingly, SMM-189 and AEA exhibited a 65% cell death compared to a 90% 
cell death observed with HU-308 at highest concentration of 100 µM, suggesting SMM-
189 and AEA are less toxic to hPDLFs. Treatment of hPDLFs with SMM-189 1 hour 
post stimulation with P.g. LPS, TNF-α, or IL-1β resulted in a significant IL-6 decrease in 






Figure 2-2. Metabolic Activity for P.g. LPS (1µg/ml), TNF-α (10ng/ml), IL-1β 
(1ng/ml) Stimulated hPDLFs 
 
Human PDLFs measured using the CCK-8 assay after exposing cells to stimuli for 24 








Figure 2-3. Baseline Responses of hPDLFs to Stimulation with P.g. LPS (1µg/ml), 
TNF-α (10ng/ml), IL-1β (1ng/ml) for 24 hr   
 
The effect of stimulus on IL-6 (A) and MCP-1 (B) expression were evaluated using 
Mesoscale Discovery V-Plex IL-6 and MCP-1 plates. The data are presented as the mean 






Figure 2-4. Time Course of IL-6 Expression in P.g. LPS (1µg/ml) Stimulated 
hPDLFs 
 
Expression levels of IL-6 were measured at 6, 12, and 24 hr using a Mesoscale Discovery 









Figure 2-5. Measurement of Cytotoxicity of AEA, SMM-189, and HU308 on 
hPDLFs 
 




M and cell 
viability was measured 18 hours later via the CCK-8 assay.  AEA, SMM-189, and HU308 
exhibited EC50 values of 16µM, 13µM, and 7.3µM respectively.  The data are presented as 







 Figure 2-6. The Effects of AEA on P.g. LPS, TNF-α, IL-1β Stimulated Production 
of IL-6 (A) and MCP-1 (B) in hPDLFs 
 
Cells were treated with stimuli 1 h before addition of 16µM of AEA then assayed 
24 hr later. AEA alone significantly increased IL-6 levels compared to control.   
Treatment with AEA in P.g.LPS stimulated cells had no significant effect on IL-6 
expression.  IL-6 expression was significantly decreased for AEA + TNF-α, AEA 
+ IL-1β -stimulated. AEA alone were not significantly affected MCP; however, 
AEA + P.g. LPS, AEA + TNF-α, AEA + IL-1β resulted in a significantly reduction 
following stimulus.  The data are presented as the mean of 3 experiments and error 




(p<0.0001) treatment groups (Figure 2-7).  Treatment of hPDLFs with SMM-189 alone 
did not affect expression levels of IL-6 (Figure 2-7) or MCP-1(Figure 2-7).  MCP-1 
expression in stimulated cells was significantly reduced or abolished in the SMM-189 + 
P.g. LPS (p<0.0001), SMM-189 + TNF-α (p<0.0001), SMM-189 + IL-1β (p<0.0001) 
treatment groups (Figure 2-7).  
 
HU308 was also effective in suppressing IL-6 and MCP-1 induced by P.g. LPS, 
TNF-α, and IL-1β. The hPDL fibroblasts treated with HU-308 1 hour post P.g. LPS, 
TNF-α, and IL-1β stimulation resulted in a significant decrease in IL-6 in the HU308 + 
P.g. LPS (p<0.001), HU308+ TNF-α (p<0.05), HU308+ IL-1β (p<0.0001) groups with 
no effect observed with HU-308 alone (Figure 2-8).  Treatment with HU-308 also 
significantly inhibited the expression of MCP-1 in HU308+ P.g. LPS (p<0.0001), 
HU308+ TNF-α (p<0.0001), HU308+ IL-1β (p<0.0001) (Figure 2-8) with no effect 
using HU-308 alone (Figure 2-8.).   
 
 
Discussion and Summary 
 
The objective of this study was to determine if targeting the endocannabinoid 
system, specifically the CB2 receptor, could offer a new therapeutic approach for treating 
chronic inflammation in periodontal disease. Our studies were prompted by reports that 
the CB1 and CB2 receptors are upregulated in inflamed gingival fibroblasts [231].  While 
mRNA for CB1 was detected in gingival tissue from healthy, gingivitis and periodontitis 
patients, levels were higher in gingivitis and periodontitis patients. On the other hand, 
CB2 mRNA was not detected in healthy donors but was upregulated in gingivitis and 
periodontitis patients.   Additionally, hPDL cells taken from a healthy donor exhibited a 
significant increase in CB2 mRNA when induced with LPS [230, 231, 257]. 
Endocannabinoids AEA and 2-arachidonoyl glycerol (2-AG) were detected in gingival 
crevicular fluid (GCF) of patients who underwent periodontal surgery. However, only 
AEA levels were significantly increased 3 days after surgery when compared to 2-AG.  
These reports suggested that the endocannabinoid system is active in patients with PD.  
These proofs of principle studies demonstrate that ligands of CB2 act as effective anti-
inflammatory agents in stimulated hPDLFs 
 
The significant inhibition of IL-6 and MCP-1 production in P.g. LPS-, IL-1β-, 
and TNF-α- stimulated primary hPDLFs by SMM-189 and HU-308 in our studies has 
important implication in the progression of PD.  The production of cytokines after 
exposure to LPS plays an important role in periodontal disease. In periodontitis, the 
destruction of the bone is initiated via the pro-inflammatory response to bacterial 
components such as LPS and pathogen associated molecular pattern (PAMP) [223, 258]. 
The proinflammatory cytokines IL-1β and TNF-α are pivotal in the context that they are 
involved with tissue destruction and alveolar bone resorption [259]. IL-1β and TNF-α 
amplify the effects of other inflammatory markers within fibroblasts [260, 261] and are 
upregulated during periodontal inflammation and in gingival crevicular fluid [262-264].  






Figure 2-7. The Effects of SMM-189 on P.g. LPS, TNF-α, IL-1β Stimulated 
Production of IL-6 (A) and MCP-1 (B) in hPDLFs 
 
Cells were treated with stimuli 1 h before addition of 13µM of SMM-189 then assayed 24 
hr later. SMM-189 alone had no significant effects on IL-6 of MCP-1 expression.  
Significant decreases in expression were measured in the SMM-189 + P.g. LPS, SMM-189 
+ TNF-α, SMM-189 + IL-1β groups for IL-6-and MCP-1. The data are presented as the 






Figure 2-8. The Effects of HU308 on P.g. LPS, TNF-α, IL-1β Stimulated 
Production of IL-6 (A) and MCP-1 (B) in hPDLFs 
 
Cells were treated with stimuli 1 h before addition of 7.3 µM of HU-308 then assayed 24 hr 
later. HU308 alone had no significant effects on the expression of IL-6 and MCP-1.  
Significant decreases in expression were measured in the HU308 + P.g. LPS, HU308 + 
TNF-α, HU308 + IL-1β - groups for IL-6 and MCP-1. The data are presented as the mean 




[265, 266] and levels are higher in patients with periodontitis compared to patients with 
gingivitis [236]. Furthermore, increased levels of IL-6 were found in the crevicular fluid 
of inflamed periodontal pockets compared with healthy sites [235].  In human gingival 
epithelial cells P. gingivalis sonic extract induced secretion of IL-8 and MCP-1 [267].  
MCP-1 acts as a potent chemoattractant for recruiting macrophages, memory T cells and 
dendritic cells to the sites of inflammation caused by tissue injury or infection [268, 269].  
 
The cannabinoid receptors manifest additional benefits in PD, which are outside 
the scope of this study but warrant discussion.  The CBs are also involved in bone 
metabolism, and are widely expressed in osteoblasts and osteoclasts [164].  The reduction 
of IL-6, a potent activator of osteoclasts by CB2 selective ligands, supports bone 
formation, and cannabinoids accelerate the mineralization seen in hPDL cells [270].   In a 
cell proliferation assay using human gingival fibroblasts (hGF), AEA promoted hGF 
proliferation via CB1 and CB2 receptors [231], while AEA and 2-AG in another study 
did not exhibit significant effects on the proliferation or viability of hPDL cells [250]. 
AEA and 2-AG are reported to have different effects on proliferation and viability 
depending on the cell type [230, 231, 250, 271]. Daily administration of anandamide 
analog methanandamide in a rat periodontal disease model, exhibited beneficial effects,  
reducing TNF-α and significantly diminishing alveolar bone loss [272]. Therefore, 
reduction of the inflammatory response with cannabinoids may potentially influence the 
bone levels in PD by promoting osteoblastic activity.  In sum, the PDL is central to the 
structural integrity of the periodontium, which connects the root to the alveolar bone and 
cells within the PDL regulate bone modeling [273, 274]. Thus, the development of 






CHAPTER 3.    THE DOWNREGULATION OF CYTOKINE IN AN IN VITRO 





The study with IL-6 and MCP-1 provided proof of principle that selective CB2 
ligands are effective anti-inflammatory agents for regulation of periodontal inflammation. 
It was seen that both agonist and inverse agonist were effective in down-regulating P.g. 
LPS-, IL-1β- and TNF-α-stimulated IL-6 and MCP-1 levels in primary hPDLFs. While 
AEA exhibited a pro-inflammatory response in hPDLFs but under stimulus activation by 
P.g. LPS, TNF-α, or IL-1β it seemed to exert anti-inflammatory effects.  The effective 
inhibition of IL-6 and MCP-1 production by CB2 ligands demonstrates that targeting the 
endocannabinoid system may prove to be an efficient way to treat chronic inflammation 
in PD. However, it is rarely the case that a single cytokine or chemokine are involved in 
the progression of any disease state. There has yet to be a detailed measurement of the 
spectrum of cytokine expression at the protein levels in hPDLFs.  Such knowledge is 
critical to the understanding of the initiation and progression of PD.  Additionally, for the 
development of a new therapeutic intervention, it is critical to select the compounds with 
the highest efficacy in regulation the inflammatory cascades in PD. Furthermore, since 
IL-1β is implicated in the pathogenesis of chronic periodontitis [275] and exhibits the 
most robust cellular response in hPDLFs, it was chosen as the stimulus of choice for rest 





Cytokines are small protein molecules that function by interacting with specific 
cells and help with communication within the local environment [276]. Elevated levels of 
certain cytokines serve as biomarkers [277], and the severity of PD directly correlates 
with salivary levels of IL-1β [278]. The cytokines chosen for this study are found in 
many disease states and disorders but are not limited to inflammatory responses and 
immune cell regulation, and can be involved with other biological processes. The 
objective of the studies was to identify the greatest functionally active drug at CB2 
receptor providing the best anti-inflammatory activity in stimulated hPDLFs.  
Furthermore, since AEA is expressed in PD it was also sought to identify any beneficial 
or harmful effects of the endogenous ligand in chronic inflammation involved with PD.  
To this end the expression levels of the following cytokines were assayed : human 
interferon gamma (IFNγ), interleukin-1alpha (IL-1α), IL-1β, interleukin-2 (IL-2), 
interleukin-4 (IL-4), interleukin-5 (IL-5), IL-6, interleukin-7 (IL-7), interleukin-10 (IL-
10), interleukin-12p70 (IL-12p70), interleukin-12/ interleukin-23 p40, (IL-12/IL-23p40), 
interleukin-13 (IL-13), interleukin-15 (IL-15), interleukin-16 (IL-16), interleukin-17A 
(IL-17A), TNF-α and β, granulocyte-macrophage colony stimulating factor (GM-CSF), 








Cell Culture of Primary Human Periodontal Ligament Fibroblasts 
 
Primary human periodontal ligament fibroblasts (hPDLF) were purchased from 
Lonza [Walkersville, MD (CC-7049)]. Cell were cultured at 37°C and 5% CO2 in air in 
stromal cell basal medium (Lonza SCBM, CC-3204), as recommended by the 
manufacturer, containing 5% fetal bovine serum (FBS) and SingleQuot Kit Supplements 
& Growth Factors (Lonza SCGM, CC-4181) (growth medium). The cells were derived 
from periodontal ligament tissue obtained from healthy individuals who were negative 
for HIV-I, Hepatitis B Virus and Hepatitis C Virus. The cells had a spindle-like 
morphology and were further validated as fibroblasts via pan cytokeratin staining by 
Lonza. Experiments were performed when the cells were at 70-80% confluent, in 





Cytotoxicity details were determined and provided in Chapter 2. 
 
 
Effects of IL-1β ± SMM-189, HU-308, and AEA on Cytokine 
 
To produce the PDLF-conditioned media in which cytokines were measured, the 
cells were seeded at densities of 20,000 cells/well in growth medium in Corning Biostar 
96-well polystyrene flat bottom plates. This medium was removed after 24 hr and 
changed to SCBM basal medium containing 1% FBS, penicillin (100U/ml), and 
Streptomycin (100 µg/ml) (P/S) for another 24 hr at 37°C, 5% CO2 to synchronize the 
cells. The third day, 1% FBS SCBM basal medium with 1% P/S containing 2 ng/ml of 
IL-1β (Final concentration of 1ng/ml) was added to each well. An hour later, the addition 
of 50 µl of SCBM containing 5X EC50 and 1X IL-1β of SMM-189, HU-308, or AEA 
was performed. The conditioned medium was then removed after incubation of 24 hr.  
Using Mesoscale Discovery Human Pro-Inflammatory Panel 1 V-Plex kit (K15049D) 
and Human Cytokine Panel 1 V-Plex kit (K15050D) we tested human interferon gamma 
(IFNγ), interleukin-1alpha (IL-1α), IL-1β, interleukin-2 (IL-2), interleukin-4 (IL-4), 
interleukin-5 (IL-5), IL-6, interleukin-7 (IL-7), interleukin-10 (IL-10), interleukin-12p70 
(IL-12p70), interleukin-12/ interleukin-23 p40, (IL-12/IL-23p40), interleukin-13 (IL-13), 
interleukin-15 (IL-15), interleukin-16 (IL-16), interleukin-17A (IL-17A), TNF-α and β, 
granulocyte-macrophage colony stimulating factor (GM-CSF), and vascular endothelial 
growth factor (VEGF). Plates were analyzed for levels of cytokines according to 








Biomarkers were calculated for each group and were compared between 2 groups 
using One-way ANOVA (non-parametric) Bonferroni’s test. Values represent at least 
three biological replicates and are presented as means ± SEM. Data were analyzed using 
Graphpad Prism 6.0, statistical significance and cytokines exhibiting a p value P ≤ 0.05 






IL-1β Induced hPDLF Cytokine Production 
 
Exposure of the hPDLFs to IL-1β for 24 hours stimulated the production of 8 of 
the 19 cytokines analyzed (Figure 3-1).  Specifically, the levels of IFNγ (p<0.0001), IL-
1β (p<0.0001), IL-2 (p<0.0001), IL-6(p<0.0001), IL-13(p<0.001), TNF-α (p<0.0001), 
GM-CSF (p<0.0001), VEGF (p<0.0001) (Figure 3-1) were increased significantly 
compared to control. These 8 cytokines were further tested and against cannabinoid 
ligands at their EC50 to evaluate their respective inhibition profiles. 
 
 
Inhibition of IL-1β Induced Cytokine Production by AEA 
 
It has been reported that AEA inhibits P.g. LPS-induced production of IL-6, IL-8 
and MCP-1 in human gingival fibroblasts and that 10 µM AEA completely blocked LPS-
induced NF-kB activity [230]. However, 2-AG an endocannabinoid had opposing effects 
and increased the gene expression and production of IL-6, IL-8, and MCP-1 [250].  To 
confirm the endocannabinoid AEA was indeed an anti-inflammatory agent, AEA was 
administered 1 hour after of IL-1β addition to hPDLFs to stimulate pathology wherein 
AEA is expressed in response to insult. The combination of AEA + IL-1β treatment on 
hPDLFs significantly increased levels for IFNγ (p<0.01) (Figure 3-2), while significantly 
decreasing IL-1β (p<0.05) levels (Figure 3-3). The levels of IL-2 were unaffected 
(Figure 3-4), while a significant rise in IL-6 (p<0.0001) (Figure 3-5) was observed. The 
levels of IL-13 did not have a significantly change (Figure 3-6), while TNF-α (p<0.05) 
levels exhibited a significant rise (Figure 3-7). The levels of GM-CSF (Figure 3-8) did 
not exhibit any significant change but an increase in VEGF levels (p<0.0001) (Figure 
3-9) was observed compared to IL-1β treated hPDLFs.  
 
 
Inhibition of IL-1β Induced Cytokine Production by Synthetic CB2 Ligands 
SMM189 and HU-308 
 
The response of hPDLF to treatment with CB2 inverse agonist SMM-189 and the 
selective CB2 agonist HU-308 at the EC50 concentrations following IL-1β administration 





Figure 3-1. Baseline Responses of hPDLFs to Stimulation IL-1β (1ng/ml) for 24 hr 
 
The effects of stimulus levels on IFNγ (p<0.0001), IL-13(p<0.01), IL-1β (p<0.0001), IL-
2 (p<0.0001), IL-6(p<0.0001), TNF-α (p<0.0001), GM-CSF (p<0.0001), VEGF 
(p<0.0001) (Figure) were increased significantly compared to control. The data represents 
a minimum of 3 experiments and are presented as the standard error of mean (SEM). 








Figure 3-2. The Effects of IL-1β Stimulated hPDLFs on the Production of IFN-γ 
 
Cells were treated with stimuli 1 h before addition AEA, SMM-189, HU308 then assayed 
24 hr later. Blue is control, while Red is IL-1β treatment alone. AEA is orange, SMM-189 is 
green, while HU308 is black. IL-1β alone significantly increased IFN-γ levels compared 
to control.  Treatment with AEA + IL-1β increased IFN-γ significantly compared to IL-1β 
-stimulated. SMM-189 + IL-1β resulted in a significantly reduction following stimulus. 
While HU-308 + IL-1β also exhibited reduction following stimulus.  The data are 








Figure 3-3. The Effects of IL-1β Stimulated hPDLFs on the Production of IL-1β 
 
Cells were treated with stimuli 1 h before addition AEA, SMM-189, HU308 then assayed 
24 hr later. Blue is control, while Red is IL-1β treatment alone. AEA is orange, SMM-189 is 
green, while HU308 is black. IL-1β alone significantly increased IL-1β levels compared to 
control.  Treatment with AEA + IL-1β decrease IL-1β significantly compared to IL-1β -
stimulated. SMM-189 + IL-1β resulted in a significantly reduction following stimulus. 
While HU-308 + IL-1β also exhibited reduction following stimulus.  The data are 








Figure 3-4. The Effects of IL-1β Stimulated hPDLFs on the Production of IL-2 
 
Cells were treated with stimuli 1 h before addition AEA, SMM-189, HU308 then assayed 
24 hr later. Blue is control, while Red is IL-1β treatment alone. AEA is orange, SMM-189 is 
green, while HU308 is black. IL-1β alone significantly increased IL-2 levels compared to 
control.  Treatment with AEA + IL-1β did not show any significance and was comparable 
to IL-1β -stimulated. SMM-189 + IL-1β resulted in a significantly reduction following 
stimulus. While HU-308 + IL-1β also exhibited reduction following stimulus.  The data 







Figure 3-5. The Effects of IL-1β Stimulated hPDLFs on the Production of IL-6 
 
Cells were treated with stimuli 1 h before addition AEA, SMM-189, HU308 then assayed 
24 hr later. Blue is control, while Red is IL-1β treatment alone. AEA is orange, SMM-189 is 
green, while HU308 is black. IL-1β alone significantly increased IL-6 levels compared to 
control.  Treatment with AEA + IL-1β increase the IL-6 levels significantly compared to 
IL-1β -stimulated. SMM-189 + IL-1β resulted in a significantly reduction following 
stimulus. While HU-308 + IL-1β also exhibited reduction following stimulus.  The data 







Figure 3-6. The Effects of IL-1β Stimulated hPDLFs on the Production of IL-13 
 
Cells were treated with stimuli 1 h before addition AEA, SMM-189, HU308 then assayed 
24 hr later. Blue is control, while Red is IL-1β treatment alone. AEA is orange, SMM-189 is 
green, while HU308 is black. IL-1β alone significantly increased IL-13 levels compared to 
control.  Treatment with AEA + IL-1β did not exhibit any significant change compared to 
IL-1β -stimulated. SMM-189 + IL-1β resulted in a significantly reduction following 
stimulus. While HU-308 + IL-1β also did not exhibit any significant change compared to 








Figure 3-7. The Effects of IL-1β Stimulated hPDLFs on the Production of TNF-α 
 
Cells were treated with stimuli 1 h before addition AEA, SMM-189, HU308 then assayed 
24 hr later. Blue is control, while Red is IL-1β treatment alone. AEA is orange, SMM-189 is 
green, while HU308 is black. IL-1β alone significantly increased TNF-α levels compared 
to control.  Treatment with AEA + IL-1β increase the TNF-α levels significantly 
compared to IL-1β -stimulated. SMM-189 + IL-1β resulted in a significantly reduction 
following stimulus. While HU-308 + IL-1β also exhibited reduction following stimulus.  








Figure 3-8. The Effects of IL-1β Stimulated hPDLFs on the Production of GM-
CSF 
 
Cells were treated with stimuli 1 h before addition AEA, SMM-189, HU308 then assayed 
24 hr later. Blue is control, while Red is IL-1β treatment alone. AEA is orange, SMM-189 is 
green, while HU308 is black. IL-1β alone significantly increased IL-13 levels compared to 
control.  Treatment with AEA + IL-1β did not exhibit any significant change compared to 
IL-1β -stimulated. SMM-189 + IL-1β resulted in a significantly reduction following 
stimulus. While HU-308 + IL-1β also resulted in a significantly reduction following stimulus 
compared to IL-1β -stimulated.  The data are presented as the mean of at least 3 







Figure 3-9. The Effects of IL-1β Stimulated hPDLFs on the Production of VEGF 
 
Cells were treated with stimuli 1 h before addition AEA, SMM-189, HU308 then assayed 
24 hr later. Blue is control, while Red is IL-1β treatment alone. AEA is orange, SMM-189 is 
green, while HU308 is black. IL-1β alone significantly increased TNF-α levels compared 
to control.  Treatment with AEA + IL-1β increase the VEGF levels significantly 
compared to IL-1β -stimulated. SMM-189 + IL-1β resulted in a significantly reduction 
following stimulus. While HU-308 + IL-1β also exhibited reduction following stimulus.  





resulted in a significant decrease for all the cytokines that exhibited significant 
upregulation with IL-1β. The SMM-189 + IL-1β group significantly decreased IFNγ 
(p<0.0001) (Figure 3-2), IL-1β (p<0.0001) (Figure 3-3), IL-2 (p<0.0001) (Figure 3-4), 
IL-6(p<0.0001) (Figure 3-5), IL-13(p<0.01) (Figure 3-6), TNF-α (p<0.0001) (Figure 
3-7), GM-CSF (p<0.0001) (Figure 3-8), VEGF (p<0.0001) (Figure 3-9) compared to IL-
1β treated hPDLFs. On the other hand, treatment of hPDLFs with HU308 1 hour post 
stimulation with IL-1β resulted in a significant decrease in 7 out of 8 cytokines that were 
upregulated with IL-1β. A significantly decreased IFNγ (p<0.01) (Figure 3-2), IL-1β 
(p<0.001) (Figure 3-3), IL-2 (p<0.05) (Figure 3-4), IL-6(p<0.05) (Figure 3-5), TNF-α 
(p<0.01) (Figure 3-7), GM-CSF (p<0.0001) (Figure 3-8), VEGF (p<0.0001) (Figure 
3-9) compared to IL-1β treated hPDLFs was observed. 
 
 
Discussion and Summary 
 
The inflammatory response activates many cytokines and chemokines that are 
produced locally to fight infection and disease. Cytokines involved in a wide array of 
biological activity such as inflammation, immunomodulation, metabolic, and hemopoetic 
activity [277, 279]. These small polypeptides are expressed by various cells such as 
macrophage/monocytes, dendritic cells, neutrophils, T and B lymphocytes, endothelial 
cells as well as fibroblasts to fight off invaders. Host responses to pathogenic infection 
are involved in a highly complex network of biological activity and the intricate 
disruption of balance between pro-inflammatory and anti-inflammatory can cause loss of 
homeostatic control that may result in the system favoring a pro-inflammatory state. 
Therefore, immunomodulatory activity of cannabinoids is a good way to regulate the pro-
inflammatory response.  
 
 
Pro-Inflammatory Cytokines IL-6, IFNγ, IL-1β. and TNF-α 
 
In this study, there was a significant increase in the production of IL-6 in IL-1β-
stimulated hPDLFs compared to control. SMM-189 and HU-308 treatment produced a 
significant suppression of IL-6. Interestingly, AEA exhibited a significant upregulation of 
IL-6 under stimulation. This was surprising as AEA in chapter 2 suppressed IL-6 in IL-
1β-stimulated hPDLFs and it was AEA treatment alone that increased IL-6 levels 
significantly over control. Based upon our current data, we had a much higher IL-6 
response compared to our previous study. The reason for the differential response might 
be due heterogeneity within fibroblasts [280] or an increase in secreted levels of IL-6 
receptor (sIL-6R) that is soluble in a biological samples and can make sIL-6 levels bound 
and unavailable for detection by the antibodies [281]. IL-6 is a very important biomarker 
that is involved with many disease processes and is associated with migration of 
inflammatory cells that also is a potent activator of osteoclastogenesis [254, 265, 266]. 
IL-6 levels are increased in gingival crevicular fluids of inflamed periodontal pockets 
compared with healthy sites [235], while patients with periodontitis exhibit a higher level 




Other important cytokines affecting activation of the immune response are the 
proinflammatory IFNγ, IL-1β and TNF-α, which all exhibited significant upregulation 
following stimulation and which were significantly inhibited by SMM-189 and HU308 
treatments. In contrast, while AEA did significantly suppress stimulated IL-1β 
production, it upregulated both IFNγ and TNF-α significantly, suggesting a 
proinflammatory nature of this compound. The pro-inflammatory markers IL-6, IFNγ, 
IL-1β and TNF-α are all pyrogenic cytokines that are involved with the induction of 
prostaglandins [282]. IFNγ is involved with B-cell maturation and promotes the 
stimulation of binding the antigen-presenting cells [283-285]. Expression levels of IFNγ 
in GCF samples exhibited an increase in progressive periodontal lesions in chronic 
periodontitis patients [286].  Meanwhile, the proinflammatory activity of IL-1β and TNF-
α is well established and both are involved in tissue destruction and alveolar bone 
resorption [259]. In an inflammatory state, IL-1β is produced by activated macrophages 
[287] and promotes the release of IL-2 by T-cells and dendritic cells, that regulates T-cell 
proliferation and is crucial for the maturation of B-cells, while also stimulating fibroblast 
activity by upregulating fibroblast growth factor activity [288, 289]. IL-1β and IFNγ 
promotes the type 1 T-helper cell (Th1) phenotype, while inhibiting the development of 
type 2 T-helper cells (Th2) [290]. This is consistent with our findings that IL-1β 
stimulation did not cause stimulation of IL-4, IL-5, or IL-10 response in hPDLFs (many 
of these cytokines are implicated in the activation of the Th2 function) [291].  In sum, the 
down-regulation of these markers by CB2 agonist and inverse agonist may yield a 
beneficial therapy to prevent bone loss in PD. 
 
 
Cytokines IL-13, IL-2, GM-CSF, and VEGF 
 
Interestingly, in our study IL-13 was upregulated in IL-1β-stimulated hPDLFs and 
was effectively inhibited by SMM-189, while HU308 and AEA did not have any 
significant effects.  The upregulation of IL-13 by IL-1β stimulation is interesting when 
considering that serum from patients with periodontitis, the level of IL-13 levels are not 
significantly upregulated compared to healthy patients [292].  However, since the 
literature reports that the activation of IL-13 is involved with Th2 function and inhibits 
monocytes/macrophage proinflammatory cytokines [293], it would be counterintuitive 
for it to be upregulated by IL-1β. However, in human airway fibroblasts [294] IL-13 does 
induces eotaxin-1 (chemotactic for eosinophils), which is found to be higher in serum of 
periodontitis patients compared to healthy patients [292].  The levels of IL-2 were 
significantly decreased by SMM-189 and HU308 treatment, while AEA had no effect. 
IL-2 is a very important marker as it is involved with the maturation and proliferation of 
T-lymphocytes [295]. Upon activation of T-lymphocytes by encountering an antigen 
presenting cell, T-lymphocytes may develop into either cytotoxic T-cells, Th1 or Th2 
cells. The formation of Th1 is involved with gingival inflammation and exhibits direct 
and indirect involvement of T-cells for bone resorption seen in periodontitis [296]. 
Additionally, GM-CSF is involved in numerous inflammatory diseases, periodontitis and 
autoimmune disorders [297]. The activity of GM-CSF helps growth and differentiation of 
hematopoietic precursors such as eosinophils, granulocyte, macrophages, microglia, and 
erythrocytes [298, 299]. In Porphyromonas gingivalis-induced experimental periodontitis 
 
46 
GM-CSF -/- mice exhibited decreased bone resorption and macrophage infiltration, while 
decreasing levels of T-cell specific cytokines compared to wild type mice. The results 
suggest that GM-CSF is involved with the progression of experimental periodontitis and 
may regulate macrophage mechanisms [300]. The synthetic cannabinoids SMM-189 and 
HU-308 had an inhibitory effect on the levels of GM-CSF, while AEA again failed to 
show any effects. Thus SMM-189 and HU-308 would provide beneficial effects by 
reducing the progression of PD. VEGF induces endothelial cell proliferation and 
promotion of cell migration, permeabilization of blood vessels, and high levels of VEGF 
are indicative of PD [301-304].VEGF is an angiogenic biomarker that is crucial growth 
factor involved in angiogenesis, vasculogenesis, hemostasis, wound healing, tumor 
proliferation and endothelial cell growth. Basal levels of VEGF in hPDLFs were higher 
compared to other control biomarkers. It is reasonable that hPDLFs would indicate 
constitutive activity given PDL is a very dynamic tissue [273, 274] that constantly 
changes due to the forces of mastication and requires a consistent supply of nutrients. 
Therefore, elevated constitutive production of VEGF might be needed to sustain the high 
nutritional demands of the PDL tissue in the disease state. In IL-1β-stimulated hPDLFs, a 
significant rise in VEGF levels was observed and SMM-189 and HU-308 both were very 
effective in reducing levels similar to seen in control. However, AEA exhibited the 
opposite response and significantly increased the levels of VEGF. The increase in VEGF 
is associated with oral cancers[305] and is indicative of periodontitis[306]. Attenuation of 
VEGF in IL-1β-stimulated hPDLFs by SMM-189 and HU-308 provides mean to mitigate 
inflammation by reduction of unnecessary angiogenesis.    
 
 
The Comparison of GCF and hPDLFs Responses 
 
Human PDLFs behave like immune cells and are amplifiers of inflammatory 
signaling [260, 261] that increase the activity for destructive processes in periodontal 
inflammation. There is insurmountable evidence indicating predicative value of cytokine 
involvement in periodontitis. However, some methodological issues of collecting 
gingival crevicular fluid from patients and reporting total amount or GCF volume 
collected has led to great discrepancies. A systematic review indicates that GCF levels of 
the cytokines IFNγ, IL-1β, and IL-6 are all significantly higher in subjects diagnosed with 
chronic periodontitis compared to healthy subjects [307]. This is the first study to look at 
these cytokines and the immunosuppressive effects of cannabinoids in hPDLFs. It is also 
encouraging to see that both the CB2 agonist and the inverse agonist exhibit suppression 
of proinflammatory cytokines, while AEA has perplexing dual effects behaving as anti-






CHAPTER 4.    THE DOWNREGULATION OF CHEMOKINES IN AN IN VITRO 





The aim of this study was to extend the results from Chapter 3 and explore the 
roles of chemokines involved in local inflammation of the periodontium which have not 
been studied in detail. Chemokines are a family of cytokines that induce direct 
chemotaxis. The chemokine family is divided into 4 groups: C, CC, CXC, and CX3C 
chemokines; in these designations C is cysteine and X is any other amino acid [308]. 
Systemic effects of PD are accompanied by a rise in levels of inflammatory mediators 
related to chemotaxis of white blood cells [309, 310].  Some studies have attempted to 
measure the circulating levels of chemokines and cytokines in PD.  Interestingly, the 
levels of cytokines in blood of periodontitis patients exhibited slight differences between 
control and disease but it was not significant. A significant change was observed in the 
levels of chemokines, which resulted in upregulation of eotaxin-1 and MIG (monokine 
induced by IFNγ), while a reduction in RANTES was observed [311]. Another study 
reported increases in the levels of eotaxin and MCP-1 in serum from patients with PD 
[292]. Therefore, chemokines are very important mediators involved with local and 
systemic effects of PD and no efficacious therapies to date has been able to efficiently 
target the inflammatory pathways involved in PD. In the present study, hPDLFs were 
stimulated with IL-1β, and the levels of the following chemokines were determined: 
Human Eotaxin-1 (CCL11), MIP-1β (CCL4), Eotaxin-3 (CCL26), TARC (CCL17), IP-







Cell Culture of Primary Human Periodontal Ligament Fibroblasts 
 
Primary human periodontal ligament fibroblasts (hPDLFs) were purchased from 
Lonza [Walkersville, MD (CC-7049)]. Cell were cultured at 37°C and 5% CO2 in air in 
stromal cell basal medium (Lonza SCBM, CC-3204), as recommended by the 
manufacturer, containing 5% fetal bovine serum (FBS) and SingleQuot Kit Supplements 
& Growth Factors (Lonza SCGM, CC-4181) (growth medium). The cells were derived 
from periodontal ligament tissue obtained from healthy individuals who were negative 
for HIV-I, Hepatitis B Virus and Hepatitis C Virus. The cells had a spindle-like 
morphology and were further validated as fibroblasts via pan cytokeratin staining by 
Lonza. Experiments were performed when the cells were at 70-80% confluent, in 







Cytotoxicity details were determined and provided in Chapter 2. 
 
 
Effect of IL-1β ± SMM-189, HU-308, AEA on Chemokines 
 
To produce the PDLF-conditioned media in which cytokines were measured, the 
cells were seeded at densities of 20,000 cells/well in 5 % growth medium in Corning 
Biostar 96-well polystyrene flat bottom plates. This medium was removed after 24 hr and 
changed to SCBM basal medium containing 1% FBS, penicillin (100U/ml), and 
Streptomycin (100 µg/ml) (P/S) for another 24 hr at 37°C, 5% CO2 to synchronize the 
cells. The third day, 1% FBS SCBM basal medium with 1% P/S containing 2 ng/ml of 
IL-1β (Final concentration of 1ng/ml) was added to each well. An hour later, the addition 
of 50 µl of SCBM containing 5X EC50 and 1X IL-1β of SMM-189, HU-308, or AEA 
was performed. The conditioned medium was then removed after incubation of 24 hr.  
Using Mesoscale Discovery Human Chemokine Panel 1 V-Plex kit (K15047D) we tested 
Human Eotaxin-1 (CCL11), MIP-1β (CCL4), Eotaxin-3 (CCL26), TARC (CCL17), IP-
10 (CXCL10), MIP-1α (CCL3), IL-8 (CXCL8), MCP-1 (CCL2), MDC (CCL22), MCP-4 
(CCL13).  Plates were analyzed for levels of cytokines according to manufacturer’s 





Biomarkers were calculated for each group and were compared between 2 groups 
using One-way ANOVA (non-parametric) Bonferroni’s test. Values represent at least 
three biological replicates and are presented as means ± SEM. Data were analyzed using 






IL-1β Induced Chemokine Production in hPDLFs 
 
Stimulation of hPDLFs with IL-1β (1ng/ml) for 24hr was followed by 
measurement of chemokine levels in the media. All the chemokines except MCP-4 
(CCL13) were significantly upregulated by IL-1β:  Eotaxin-1 (CCL11) (P<0.0001), MIP-
1β (CCL4) (P<0.001), Eotaxin-3 (CCL26) (P<0.0001), TARC (CCL17) (P<0.01), IP-10 
(CXCL10) (P<0.0001), MIP-1α (CCL3) (P<0.0001), IL-8 (CXCL8) (P<0.0001), MCP-1 
(CCL2) (P<0.0001), MDC (CCL22) (P<0.0001) (Figure 4-1). These 9 chemokines 
which exhibited significant upregulation with IL-1β were then further evaluated for the 






Figure 4-1. Chemokine Production by hPDLFs in Response to Stimulation with IL-
1β (1ng/ml) for 24 hr   
 
The production of all chemokines was significantly increased by IL-1β compared to 
control. The data are presented as the mean of at least 3 experiments ± the standard error of 







IL-1β Induced Chemokine Production in hPDLFs and the Effects Exhibited by AEA 
 
In Chapter 3, AEA exhibited both pro-inflammatory and anti-inflammatory effects 
on cytokine production.  The duality of the effects of AEA was also observed when AEA 
was administered to IL-1β-stimulated hPDLFs.  As before, AEA was added 1 hour after 
IL-1β stimulation to better model the disease state versus prophylactic intervention. AEA 
significantly decreased IL-1β-stimulated eotaxin-1 (P<0.05) (Figure 4-2), while it had no 
significant effect on IL-1β-stimulated eotaxin-3 (Figure 4-3). A significantly increase in 
the levels of IL-8 (P<0.0001) (Figure 4-4) was seen but IP-10 (P<0.0001) (Figure 4-5), 
MCP-1 (P<0.0001) (Figure 4-6), MDC (P<0.0001) (Figure 4-7) significantly decreased 
IL-1β-stimulated chemokine levels. MIP-1α (P<0.0001) (Figure 4-8), MIP-1β 
(P<0.0001) (Figure 4-9) levels were significantly increased compared to IL-1β treated 
hPDLFs. The Thymus and activation-regulated chemokine (TARC) production (Figure 
4-10) was unaffected by IL-1β-stimulated AEA treatment. 
 
 
IL-1β Induced Chemokine Production in hPDLFs and the Effects of CB2 Synthetic 
CB2 Inverse Agonist SMM189 and Agonist HU308 
 
In the cytokine study both the synthetic CB2 ligands were effective in decreasing 
the levels of cytokine secretion in IL-1β-stimulated hPDLFs. The trend was preserved 
with HU-308 in terms of providing suppression of chemokine levels [312]; however, the 
SMM-189 administration better results in comparison to HU-308. Treatment of hPDLFs 
with SMM-189 1 hr post stimulation with IL-1β resulted in a significant decrease of the 
chemokines: eotaxin-1 (P<0.0001) (Figure 4-2), eotaxin-3 (P<0.0001) (Figure 4-3), IL-8 
(P<0.0001) (Figure 4-4), IP-10 (P<0.0001) (Figure 4-5), MCP-1 (P<0.0001) (Figure 
4-6), MDC (P<0.0001) (Figure 4-7), MIP-1α (P<0.01) (Figure 4-8), MIP-1β (P<0.0001) 
(Figure 4-9), and TARC (P<0.01) (Figure 4-10), compared to IL-1β treated hPDLFs. 
While, treatment of hPDLFs with HU308 1 hr post stimulation significantly decreased 
the levels of eotaxin-1 (P<0.0001) (Figure 4-2), eotaxin-3 (P<0.0001) (Figure 4-3), IL-8 
(P<0.0001) (Figure 4-4), IP-10 (P<0.0001) (Figure 4-5), MCP-1 (P<0.0001) (Figure 
4-6), MDC (P<0.0001) (Figure 4-7), MIP-1α (P<0.05) (Figure 4-8), MIP-1β (P<0.001) 
(Figure 4-9) and TARC (P<0.01) (Figure 4-10), compared to IL-1β treated hPDLFs. 
 
 
Discussion and Summary 
 
The destruction of the periodontal soft tissue as well as the surrounding alveolar 
bone is a result of host responses that activate various cytokines, chemokines, proteolytic 
enzymes and arachidonic acid metabolites [313]. Chemotactic factors, and their 
respective receptors play, an important role in many pathologies including rheumatoid 
arthritis [314, 315], atherosclerosis [316], and inflammatory bowel disease [317, 318].  In 
the previous two chapters, we determined that targeting the CB2 receptor in the ECS is a 
viable option for the regulation of proinflammatory cytokines in hPDLFs. However, 
chemokines are key in the recruitment of immune cells to the active site of inflammation 





Figure 4-2. The Effects of AEA, SMM-189, or HU308 on IL-1β Stimulated 
Production of Eotaxin-1 by hPDLFs 
 
Cells were treated with IL-1β for1 h before addition AEA, SMM-189, or HU308 then 
assayed 24 hr later. IL-1β alone significantly increased the level of Eotaxin-1 compared to 
control.  Treatment with AEA, SMM-189 and HU-308 significantly decreased + IL-1β-
stimulated Eotaxin-1, compared to IL-1β alone. The data are presented as the mean of at 








Figure 4-3. The Effects of AEA, SMM-189, or HU308 on IL-1β Stimulated 
Production of Eotaxin-3 by hPDLFs 
 
Cells were treated with IL-1β for1 h before addition AEA, SMM-189, or HU308 then 
assayed 24 hr later. IL-1β alone significantly increased IL-1β levels compared to control.  
Treatment with AEA + IL-1β-stimulated had no effect on Eotaxin-3, but both SMM-189, 
or HU308 significantly decreased IL-1β-stimulated Eotaxin-3 production. The data are 








Figure 4-4. The Effects of AEA, SMM-189, or HU308 on IL-1β Stimulated 
Production of IL-8 by hPDLFs 
 
Cells were treated with IL-1β for1 h before addition AEA, SMM-189, or HU308 then 
assayed 24 hr later. IL-1β alone significantly increased IL-8 levels compared to control.  
Treatment with AEA significantly increased IL-1β-stimulated IL-8 production, but both 
SMM-189 and HU-308 significantly reduced it.  The data are presented as the mean of at 







Figure 4-5. The Effects of AEA, SMM-189, or HU308 on IL-1β Stimulated 
Production of IP-10 by hPDLFs 
 
Cells were treated with IL-1β for1 h before addition AEA, SMM-189, or HU308 then 
assayed 24 hr later. IL-1β alone significantly increased IP-10 levels compared to control.  
Treatment with AEA, SMM-189, and HU-308 significantly reduced IL-1β-stimulated IP-
10 production. The data are presented as the mean of at least 3 experiments ± the standard 







Figure 4-6. The Effects of AEA, SMM-189, or HU308 on IL-1β Stimulated 
Production of MCP-1 by hPDLFs 
 
Cells were treated with IL-1β for1 h before addition AEA, SMM-189, or HU308 then 
assayed 24 hr later. IL-1β alone significantly increased MCP-1 levels compared to control.  
Treatment with AEA, SMM-189, and HU-308 significantly reduced IL-1β-stimulated 
MCP-1 production. The data are presented as the mean of at least 3 experiments ± the 







Figure 4-7. The Effects of AEA, SMM-189, or HU308 on IL-1β Stimulated 
Production of MDC by hPDLFs 
 
Cells were treated with IL-1β for1 h before addition AEA, SMM-189, or HU308 then 
assayed 24 hr later. IL-1β alone significantly increased MDC levels compared to control.  
Treatment with AEA, SMM-189, and HU-308 significantly reduced IL-1β-stimulated 
MDC production. The data are presented as the mean of at least 3 experiments ± the 







Figure 4-8. The Effects of AEA, SMM-189, or HU308 on IL-1β Stimulated 
Production of MIP-1α by hPDLFs 
 
Cells were treated with IL-1β for1 h before addition AEA, SMM-189, or HU308 then 
assayed 24 hr later. IL-1β alone significantly increased MIP-1α levels compared to control.  
Treatment with AEA significantly increased IL-1β-stimulated MIP-1α production, but 
both SMM-189 and HU-308 significantly reduced it.  The data are presented as the mean 








Figure 4-9. The Effects of AEA, SMM-189, or HU308 on IL-1β Stimulated 
Production of MIP-1β by hPDLFs 
 
Cells were treated with IL-1β for1 h before addition AEA, SMM-189, or HU308 then 
assayed 24 hr later. IL-1β alone significantly increased MIP-1β levels compared to control.  
Treatment with AEA significantly increased IL-1β-stimulated MIP-1β production, but 
both SMM-189 and HU-308 significantly reduced it.  The data are presented as the mean 








Figure 4-10. The Effects of AEA, SMM-189, or HU308 on IL-1β Stimulated 
Production of TARC by hPDLFs 
 
Cells were treated with IL-1β for1 h before addition AEA, SMM-189, or HU308 then 
assayed 24 hr later. IL-1β alone significantly increased IL-1β levels compared to control.  
Treatment with AEA + IL-1β-stimulated had no effect on TARC, but both SMM-189, or 
HU308 significantly decreased IL-1β-stimulated TARC production. The data are 






mediators in periodontitis. Here, we provide further evidence that the targeting the CB2 




Chemokines Eotaxin-1, Eotaxin-3, MIP-1α, MIP-1β, and IP-10 
 
Eotaxin-1 (CCL11) are chemotactic for eosinophils, which plays an important 
role in allergy and conditions such as asthma [319, 320], allergic rhinitis [321], and 
osteoarthritis [322]. In our current study, we found a significant rise in the level of 
eotaxin-1 in IL-1β-stimulated hPDLFs. This significant rise was ablated by SMM-189 
and HU-308 and brought down to control levels. Meanwhile, AEA treatment was not as 
potent in the suppression of eotaxin-1 compared to the synthetic CB2 ligands SMM-189 
and HU-308. It is noteworthy of the harmonious relationship seen with IL-13 and 
eotaxin-1. As shown earlier the levels of IL-13 were upregulated and are involved in the 
induction of eotaxin in human airway fibroblasts [294], which might also be true in our 
study. Eotaxin-3 (CCL26), also known as macrophage inflammatory protein 4-alpha, is 
chemotactic for basophils and eosinophils [323]. It is involved in allergy-induced asthma 
[324] and its gene is associated with rheumatoid arthritis [325]. IL-1β increased 
production of eotaxin-3 that was inhibited by both SMM-189 and HU-308, but not AEA. 
The upregulation of eotaxins may lead to an increase in inflammation via eosinophils in 
the periodontium. It is known that eosinophils play an active role in bronchial epithelial 
damage and airflow obstruction[326].  Eosinophils are polymorphonuclear leukocytes 
that have secretory eosinophil cationic protein (ECP) that is released upon infection. This 
activity of eosinophils was seen in adult periodontitis that caused secretion of ECP at 
higher rates, while patients with gingivitis did not have the same response and were not 
involved with secretion of ECP [327]. These finding indicate that recruitment of 
eosinophils by eotaxins may be a result of excessive pathogenic invasion that is seen in 
periodontitis but not gingivitis. The macrophage inflammatory protein 1-alpha and beta, 
MIP-1α (CCL3) and MIP-1β (CCL4) are very important chemoattractant for neutrophils, 
T lymphocytes, and macrophages that bind to chemokine receptor type 5 (CCR5) [328]. 
MIP-1α is produced by activated macrophages, neutrophils, B and T lymphocytes and 
fibroblasts [329], while MIP-1β is produced by macrophages, lymphocytes and other 
mature hemopoetic cells [329].  MIP-1α plays an important role in autoimmune disease 
such as rheumatoid arthritis [330], while MIP-1β also plays are role in rheumatoid 
arthritis [331] but is more involved with organ transplant rejection [332], granular 
lymphocyte leukemia [331]. The gingival crevicular fluid (GCF) of healthy individuals 
does not usually contain MIP-1α and MIP-1β [333]. However, MIP-1α and MIP-1β are 
seen in PD patient samples of gingival tissues via immunohistochemistry, while it is not 
found in healthy tissue [334]. In our study, AEA treatment led to significant upregulation 
of both MIP-1α and MIP-1β in IL-1β-stimulated hPDLFs, indicating that AEA might be 
involved with potentiation of PD and may exacerbate the condition. Meanwhile, SMM-
189 and HU-308 treatment both led to the suppression of MIP-1α and MIP-1β but SMM-
189 exerted better inhibition profile. The chemokines MIP-1α and MIP-1β levels are not 
found in healthy tissue, while it is associated with inflammatory conditions such as PD 
and multiple sclerosis (MS). Given their role in MS, both MIP-1α and MIP-1β levels are 
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significantly elevated and enhance the disease state [335]. Therefore, suppression of these 
chemokines would ameliorate the destructive effects, which are mediated via migration 
of monocytes and T-cells. Additionally, IP-10 (CXCL10) was significantly reduced by 
SMM-189, HU-308, and AEA treatments to near control levels. IP-10 is induced by a 
variety of cells that include eosinophils, human fibroblasts, neutrophils, keratinocytes and 
endothelial cells by stimuli such as IFN-γ or IL-1β [336, 337] and is chemotactic of 
monocytes/macrophages and other immune cells. IP-10 levels are seen upregulated in 
inflamed periodontal tissue [296], while treatment with cannabinoids led to a complete 
suppression of the IP-10 indicating their anti-inflammatory effects. 
 
 
Chemokines TARC, IL-8, MCP-1, and MDC 
 
Thymus and activation-regulated chemokine TARC (CCL17) is a chemotactic 
factor that activates T lymphocytes via chemokine receptor type 4 (CCR4) [338] 
particularly in CD4+ Th2 cells. TARC is associated with many diseases including 
periodontitis [339], multiple sclerosis [340], atopic dermatitis [341], esophageal 
squamous cell carcinoma [342]. TARC is recently seen the chemokine linking the 
migration of Th2 cells that mediate the exacerbation of PD[343]. In our study treatment 
with AEA exhibited some reduction of TARC level but it was not significant. 
Meanwhile, both SMM-189 and HU-308 exhibited significant reduction and were 
brought back down to near control levels. Therefore, SMM-189 and HU-308 would both 
decrease the migration of Th2 cells by reduction of TARC levels and would in turn 
alleviate the disease. IL-8 (CXCL8) is one of the most potent chemotactic factors for 
polymorphonuclear leukocytes and is produced in variety of tissues and blood cells [344, 
345]. IL-8 is associated with numerous disorders [346, 347] and is considered one of the 
main initiators of periodontal disease [348]. The treatment with AEA exhibited a strong 
effect that significantly increased IL-8 levels over IL-1β alone, while both SMM-189 and 
HU-308 treatments again reduced IL-8 to near control levels. The reduction of IL-8 levels 
would attenuate the malicious and nonspecific destruction seen by polymorphonuclear 
neutrophils (PMNs) and would restore gingival health. Furthermore, the levels of IL-8 are 
indicative and may even have predictive value for PD due to the fact it is found in 
majority of sites exhibiting PD [349]. Another important player is MCP-1 (CCL2) that 
acts as a potent chemoattractant for macrophages, memory T cells and dendritic cells to 
sites of inflammation caused by tissue injury or infection [268, 269]. MCP-1 levels were 
inhibited by SMM-189, HU-308. In GCF samples from patients with generalized 
aggressive PD, MCP-1 and RANTES were significantly elevated [350]. Also, MCP-1 in 
GCF and saliva can be a reliable indicator for the severity of periodontitis [351]. 
Therefore, inhibition of MCP-1 would lead to the decrease in initiation, mobilization and 
regulation of monocytes and result in decreased bone resorption within the periodontium.  
Macrophage derived chemokine MDC (CCL22) activates CCR4 [338] and is found in 
atopic dermatitis [341], esophageal squamous cell carcinoma [342], and causes an 
increase in the population of regulatory T cells at the affected site. In allergen induced 
lung, MDC and TARC are involved with increase of Th2 to the active site of 
inflammation [352]. If TARC and MDC behave similarly, one can speculate that MDC 
activity would also cause exacerbation of PD. In this study, MDC production was 
 
62 
completely abolished by SMM-189, HU-308, and AEA. These responses provide further 
evidence that targeting the CB2 receptor by synthetic CB2 ligands is an effective way to 
suppressing the chemokine levels seen within hPDLFs.  
 
 
Conclusions for the Study 
 
The studies that using hPDLFs strongly indicate that this component of the PDL 
plays a critical role in the recruitment of immune cells and amplification of the 
inflammatory response. The participation of the resident fibroblasts enhances production 
rates and quantity of these factors and contributes to destructive process seen in PD.  This 
is also seen in inflamed gingival tissue, which have high levels of MCP-1, IP-10, MIP-1α 
and MIP-1β and their respective chemokine receptors CCR5 and CXCR5 [334].  One 
striking result is the duality of AEA in both stimulating and inhibiting chemokine 
production.  AEA provides both a pro-inflammatory and anti-inflammatory activity in a 
tightly regulated system that led to an increased IL-8, MIP-1α and MIP-1β in IL-1β 
stimulated hPDLFs, while it suppressed MCP-1, MDC, IP-10, and Eotaxin-1. Given the 
roles of the specific chemokines, it can be inferred that AEA helps with recruitment of 
neutrophils by chemokines IL-8, MIP-1α and MIP-1β in hPDLFs. On the other hand, 
suppression of Eotaxin-1, IP-10, MCP-1, and MDC by AEA indicates it could decrease 
recruitment of eosinophils and decrease macrophages infiltration as with many biological 
cascades, the endogenous regulatory system can be overwhelmed but the disease state 
resulting in dysregulation of the system.  In chronic PD this is in fact observed and it 
likely that production of AEA is insufficient to return homeostasis to the system.  To 
overcome the limitations of the endogenous system CB2 selective synthetic ligands 
proved to exhibit excellent inhibition of chemokines produced by IL-1β-stimulated 
hPDLFs. Overall, SMM-189, an inverse agonist behaves more potently in the suppression 






CHAPTER 5.    THE DOWNREGULATION OF LEUKOCYTE ADHESION AND 
VASCULOGENIC MARKERS IN AN IN VITRO PERIODONTITIS MODEL VIA 





During the progression of periodontal disease, new endothelial cells and capillary 
formation or angiogenesis is required to form new blood vessels to supply nutrition and 
promote protein signaling during active inflammation [353]. Growth factors are released 
that play a critical role in development of new blood vessels such as vascular endothelial 
growth factor (VEGF) [353] and are found upregulated in active periodontal destruction 
compared to healthy subjects [354]. This increase in vasculature is part of the host 
response and helps leukocyte migration to the site of infection [355]. The attachment of 
leukocytes maybe seen in periodontopathogen Porphyromonas gingivalis (P. gingivalis.).   
This causes the induction of vascular cell adhesion molecule -1 (VCAM-1) expression in 
human gingival fibroblasts (hGF) and human PDL cells (hPDLCs), which is regulated by 
NF-κB and ERK1/2 signaling pathways [356]. Furthermore, strains of P. gingivalis 
induced the expression of the intercellular adhesion molecule-1 (ICAM-1) in umbilical 
vein endothelial cell line ECV-304, also upregulated by activation of NF-κB pathway 
[357]. Angiogenesis and expression of these adhesion molecules facilitate antigen 
presentation by dendritic cells and causes T helper proliferation that can further help 
induce proinflammatory cytokine production [358, 359].  Thus, the ability to regulate 
vasculogenic markers in PD would provide additional benefits to regulating the 
inflammatory response.  
 
 
Cannabinoid Regulation of Angiogenesis and Vascular Injury 
 
The NF-ĸB pathway is considered as one of the main inflammatory signaling 
pathways involved with the expression of proinflammatory genes [203]. Targeting the 
NF-ĸB pathway is considered ideal for anti-inflammatory drugs and both 
endocannabinoids and synthetic cannabinoids are known to inhibit activation of NF-ĸB 
[173, 230, 360]. Interestingly, other than the NF-ĸB pathway, cannabinoids are also 
implicated in the inhibition of migration of inflamed immune cells by CB2 receptor 
agonist via the downregulation of arachidonate 5-lipoxygenase (Alox5) [361]. Alox5 is 
involved with various inflammatory disease conditions and are essential in the 
biosynthesis of leukotrienes, which are lipid inflammatory mediators derived from 
arachidonic acid [362]. In development of periodontitis, CD4+ T lymphocytes become 
activated and increase secreted cytokine production. The presence of ICAM-1 and 
VCAM-1 increases antigen presentation for the T lymphocytes and prolong the pro-
inflammatory state. Meanwhile, cannabinoids exhibit suppression of ICAM-1 and 
VCAM-1 in brain endothelium upon viral infection and reduce microglial responses that 
decrease CD4+ T lymphocytes around blood vessels [363]. We have shown CB2 
selective ligands exhibiting novel anti-inflammatory activity in vitro in our previous 
chapters.  To further expand the analysis of biological cascades important to the 
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progression of PD, studies were conducted to measure the effects of cannabinoids on 
adhesion and angiogenic markers. The following angiogenic and vascular markers were 
tested for their activity in IL-1β-stimulated hPDLFs: VEGF/VEGFA, VEGF-C, VEGF-
D, tyrosine kinase-2 (Tie-2), fms-like tyrosine kinase (Flt-1), placental growth factor 
(PIGF), basic fibroblast growth factor (bFGF), serum amyloid A (SAA), C - reactive 






Cell Culture of Primary Human Periodontal Ligament Fibroblasts 
 
Primary human periodontal ligament fibroblasts (hPDLFs) were purchased from 
Lonza [Walkersville, MD (CC-7049)]. Cell were cultured at 37°C and 5% CO2 in air in 
stromal cell basal medium (Lonza SCBM, CC-3204), as recommended by the 
manufacturer, containing 5% fetal bovine serum (FBS) and SingleQuot Kit Supplements 
& Growth Factors (Lonza SCGM, CC-4181) (growth medium). The cells were derived 
from periodontal ligament tissue obtained from healthy individuals who were negative 
for HIV-I, Hepatitis B Virus and Hepatitis C Virus. The cells had a spindle-like 
morphology and were further validated as fibroblasts via pan cytokeratin staining by 
Lonza. Experiments were performed when the cells were at 70-80% confluent, in 





Cytotoxicity details were determined and provided in Chapter 2. 
 
 
Determining the Effects of IL-1β ± SMM-189, HU-308, and AEA on Leukocyte 
Adhesion and Vascular Biomarkers 
 
To produce the PDLF-conditioned media in which cytokines were measured, the 
cells were seeded at densities of 20,000 cells/well in 5% growth medium in Corning 
Biostar 96-well polystyrene flat bottom plates. This medium was removed after 24 hr and 
changed to SCBM basal medium containing 1% FBS, penicillin (100U/ml), and 
Streptomycin (100 µg/ml) (P/S) for another 24 hr at 37°C, 5% CO2 to synchronize the 
cells. The third day, 1% FBS SCBM basal medium with 1% P/S containing 2 ng/ml of 
IL-1β (Final concentration of 1ng/ml) was added to each well. An hour later, the addition 
of 50 µl of SCBM containing 5X EC50 and 1X IL-1β of SMM-189, HU-308, or AEA 
was performed. The conditioned medium was then removed after incubation of 24 hr.  
Using Mesoscale Discovery Human Angiogenic Panel 1 V-Plex kit (K15047D) and 
Vacular Injury Panel 2 V-Plex kit (K15198D) we tested VEGF/VEGFA, VEGF-C, 
VEGF-D, tyrosine kinase-2 (Tie-2), FMS-like tyrosine kinase (Flt-1), placental growth 
factor (PIGF), basic fibroblast growth factor (bFGF), serum amyloid A (SAA), C - 
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reactive protein (CRP), VCAM-1/CD106, ICAM-1/CD54). Plates were analyzed for 
levels of cytokines according to manufacturer’s instructions using Mesoscale SECTOR 





Biomarkers were calculated for each group and were compared between 2 groups 
using One-way ANOVA (non-parametric) Bonferroni’s test. Values represent at least 
three biological replicates and are presented as means ± SEM. Data were analyzed using 






IL-1β Induced Angiogenic and Adhesion Biomarkers in hPDLFs 
 
The hPDLFs were stimulated with IL-1β (1ng/ml) for 24hr to measure the levels 
of VEGF/VEGFA, VEGF-C, VEGF-D, tyrosine kinase-2 (Tie-2), FMS-like tyrosine 
kinase (Flt-1), placental growth factor (PIGF), basic fibroblast growth factor (bFGF), 
serum amyloid A (SAA), C - reactive protein (CRP), VCAM-1/CD106, ICAM-1/CD54). 
3 out of 11 biomarkers exhibited significant upregulation of protein levels after 
stimulation for 24hours with IL-1β. The levels of VEGF/VEGFA (P<0.0001), VCAM-1 
(P<0.01), ICAM-1 (P<0.0001) (Figure 5-1) were increased significantly compared to 
control. These biomarkers were further evaluated for using cannabinoid ligands at their 
EC50 to measure inhibitory activity. 
 
 
Effects Exhibited by AEA on Expression of Angiogenesis and Adhesion Biomarkers 
in IL-1β-Stimulated hPDLFs 
 
AEA has been shown to completely block LPS-induced NF-kB activity [230] and 
exhibit anti-inflammatory activity. However, our findings are revealing mysterious 
behavior of AEA, which has both pro-inflammatory and anti-inflammatory properties. To 
understand the role of AEA better, we evaluated angiogenic biomarkers and leukocyte 
adhesion molecules. The treatment with AEA + IL-1β did not exhibit any significant 
change on ICAM-1 (Figure 5-2) and VCAM-1 (Figure 5-3) levels, while a significant 
increase was observed in VEGF levels (P<0.0001) (Figure 5-4) compared to IL-1β 
treated hPDLFs. The VEGF response was like what was seen in our cytokine study in 
Chapter 3, which saw a rise of VEGF in AEA + IL-1β hPDLFs. Therefore, AEA 
stimulates angiogenesis VEGF in stimulated hPDLFs thus promoting angiogenesis while 
at the same inhibits the recruitment of neutrophils as evidenced by the lack of change in 







Figure 5-1. Angiogenic and Vascular Injury Markers Production by hPDLFs in 
Response to Stimulation with IL-1β (1ng/ml) for 24 hr 
 
The production of the following angiogenic and vascular injury markers were 
significantly increased by IL-1β compared to control. The data are presented as the mean 








Figure 5-2. The Effects of AEA, SMM-189, or HU308 on IL-1β Stimulated 
Production of ICAM-1 by hPDLFs 
 
Cells were treated with IL-1β for 1 hr before addition AEA, SMM-189, or HU308 then 
assayed 24 hr later. IL-1β alone significantly increased the level of ICAM-1 compared to 
control.  Treatment with AEA + IL-1β-stimulated ICAM-1 did not have any effects, 
compared to IL-1β alone. SMM-189 and HU-308 significantly reduced IL-1β-stimulated 
levels of ICAM-1.  The data are presented as the mean of at least 3 experiments ± the 







Figure 5-3. The Effects of AEA, SMM-189, or HU308 on IL-1β Stimulated 
Production of VCAM-1 by hPDLFs 
 
Cells were treated with IL-1β for 1 hr before addition AEA, SMM-189, or HU308 then 
assayed 24 hr later. IL-1β alone significantly increased the level of VCAM-1 compared to 
control.  Treatment with AEA and HU-308 + IL-1β-stimulated VCAM-1 did not have any 
significant effects, compared to IL-1β alone. SMM-189 significantly reduced IL-1β-
stimulated levels of VCAM-1.  The data are presented as the mean of at least 3 
experiments ± the standard error of mean as (SEM). *P<0.05, **P<0.01standard error of 







Figure 5-4. The Effects of AEA, SMM-189, or HU308 on IL-1β Stimulated 
Production of VEGF by hPDLFs 
 
Cells were treated with IL-1β for 1 hr before addition AEA, SMM-189, or HU308 then 
assayed 24 hr later. IL-1β alone significantly increased VEGF levels compared to control.  
Treatment with AEA significantly increased IL-1β-stimulated VEGF production, but 
both SMM-189 and HU-308 significantly reduced it.   The data are presented as the mean 





Effects of SMM189 and HU308 on Expression of Angiogenesis and Adhesion 
Biomarkers in IL-1β-Stimulated hPDLFs 
 
The synthetic CB2 ligands exhibit excellent suppression profile against cytokines 
(Chapter 3) and chemokines (Chapter 4) in IL-1β-stimulated hPDLFs. IL-1β was 
measured to be a potent inducer of VEGF, ICAM-1, and VCAM-1. The SMM-189 + IL-
1β stimulated hPDLFs significantly decreased ICAM-1 (P<0.0001) (Figure 5-2), 
VCAM-1 (P<0.05) (Figure 5-3), VEGF (Figure 5-4) compared to IL-1β treated hPDLFs 
alone. While treatment of hPDLFs 1 hr post stimulation with IL-1β then addition of HU-
308 resulted in the decrease of 2 out of 3 biomarkers. The agonist HU308 + IL-1β 
stimulated hPDLFs significantly decreased the levels of ICAM-1 (P<0.0001) (Figure 
5-2), VEGF (P<0.0001) (Figure 5-4) compared to IL-1β treated hPDLFs alone. The 
regulation of angiogenic and leukocyte adhesion markers further provides evidence that 




Discussion and Summary 
 
 
The Roles of VEGF, ICAM-1, and VCAM-1 in Disease 
 
VEGF is upregulated during inflammation and causes migration of endothelial 
cells is an active process in many pathologies [364]. Upon activation, VEGF receptors 
activate many important cellular processes including mitogenic, angiogenic and 
permeability enhancing effects [365]. The extensive distribution of VEGF in the 
periodontium supports its role in periodontal maintenance, however, in patients with 
periodontitis there is a significant increase in VEGF levels and are indicative of 
periodontal disease [304].  Furthermore, during inflammation adhesion molecules ICAM-
1 and VCAM-1 facilitate the sturdy adhesion of leukocytes for migration into the 
subendothelium [366]. The extravasation of leukocytes to inflamed tissue is further aided 
by active angiogenesis that improves permeability of blood vessels. The role of ICAM-1 
during periodontal inflammation can be correlated with the increase in the adhesion 
molecule during active inflammation [367]. ICAM-1 is widely expressed on epithelial 
cells, endothelial cells, leukocytes, monocytes, fibroblasts [368].  Meanwhile, VCAM-1 
is involved with periodontal disease [369] and is found on monocytes, endothelial and 
synovial cells [370].  
 
Stimulation of human gingival fibroblasts by tumor necrosis factor alpha (TNF-α) 
or interferon gamma (INF-γ) results in increased ICAM-1 and VCAM-1 levels which can 
be inhibited via blockade of NF-κB pathway [371]. Additionally, both ICAM-1 and 
VCAM-1 belong to immunoglobulin (Ig) superfamily that interact with specific integrin 
regions on leukocytes [372] to promote accumulation that may be associated with 
gingival and periodontal pockets [373]. Furthermore, polymorphonuclear neutrophils 
(PMNs) may be, in part, regulated by ICAM-1 promoting their transmigration to gingival 
tissue and junction epithelium [374]. The progression of periodontitis correlates with 
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other pathologies [215-218] and such is the case with rheumatoid arthritis (RA) that 
exhibits similar features to PD. It is interesting that ICAM-1, VCAM-1, and VEGF are 
also associated with RA and are upregulated with severity of the disease[375]. 
Meanwhile plasma and synovial fluid levels of ICAM-1 and VCAM-1 are significantly 
higher in RA than healthy controls [376]. Therefore, this might be hitting two birds with 
one stone, controlling the balance of VEGF, ICAM-1, and VCAM-1 expression in RA 
and PD. Thereby, regulating leukocytes entry and retention in chronic inflammation that 




Regulation of VEGF, ICAM-1, and VCAM-1 by Cannabinoids 
 
In the present study, targeting the CB2 receptor effectively downregulated the 
biomarkers ICAM-1, VCAM-1, and VEGF levels in hPDLFs. The results of this study 
provide solid grounds that activation of the CB2 receptor also leads to the decrease in 
angiogenic responses, as well as restricts leukocyte infiltration. In the previous chapters, 
AEA is seen as playing a dual role during infection/inflammation that is regulating both 
pro-inflammatory and anti-inflammatory components. The data in this study is 
synchronous and consistent with our previous findings with AEA. It causes increase in 
VEGF, that was also seen in Chapter 3, meanwhile shows no inhibition of ICAM-1 or 
VCAM-1 levels. However, CB2 selective synthetic ligands maintained their effectiveness 
against vascular and angiogenic markers in IL-1β stimulated hPDLFs. SMM-189 
suppressed VEGF, ICAM-1, and VCAM-1 levels while the agonist HU-308 only 
suppressed VEGF, ICAM-1. Therefore, SMM-189 provide a larger spectrum of 
inhibition of cytokines, chemokines, and vascular markers compared to HU-308 and the 
endocannabinoids AEA. The effective inhibition of vascular markers is a promising 
approach for preventing the movement of pathogenic lymphocytes to the site of 
inflammation caused by dysfunctional immune response. Taken together, SMM-189 
operates by suppression of cytokine and chemokine responses, while inhibiting leukocyte 
adhesion molecules and reducing angiogenesis. Pharmacological interventions to regulate 
the proinflammatory response in periodontal disease needs to target some likely key 
players that leads to the suppression of immune cells and the PDL fibroblasts immune-
like responses [377].  The inhibitory activity of synthetic cannabinoids seen in IL-1β 
stimulated hPDLFs firmly establish a secondary beneficial effect on leukocytes adhesion 











The oral epithelial barrier serves at the oral cavity’s first line of defense against 
exogenous substances, pathogens and even mechanical insults. The attached gingival 
cells found in the oral epithelium are keratinized and are connected via various adhesion 
proteins that keep the gums intact and provide a layer of defense[378]. Salivary proteins 
further protect the gingiva and the teeth from pathogens by secretory Immunoglobulin A 
(sIgA) and lactoferrins, which inhibit the bacteria[379]. However, in absence of proper 
oral hygiene, a change in the bacterial flora of the oral cavity may be observed 
characterized by complex interactions within the microbial communities to shift from 
commensal flora to a dysbiotic one. This is due to the increase in the types and number of 
pathogenic bacteria and decrease of beneficial microflora.  In polymicrobial dysbiosis 
pathogenic microbial communities help each other thrive, evade the host immunity and 
promote an inflammatory response. The host’s response to pathogenic infection 
eventually results in a loss of homeostasis as the immune system balance shifts to a pro-
inflammatory state. This pro-inflammatory state  causes tissue breakdown, which is 
advantageous for the pathogen as it derives nutrients from tissue destruction [380]. 
However, the susceptibility of the host to irreversible tissue destruction is determined by 
various factors including genetics [381], environmental factors [382], and aging [383]. It 
is this multifactorial nature of PD that makes it difficult to determine an accurate 
prognosis. 
 
During the initial manifestation of the disease, an increase in gingival crevicular 
fluid (GCF), polymorphonuclear neutrophils (PMN’s) and serum antibodies help prevent 
plaque formation. This is followed by local accumulation of lymphocytes, and within a 
few weeks’ dense infiltrate of T-lymphocytes, plasma cells and macrophages can be 
found. The latter shifts from gingivitis to periodontitis, which can be indicative of 
subsequent bone loss, attachment loss in the periodontium [355]. However, at the cellular 
level, cytokines and chemokines are produced by local immune cells and fibroblasts that 
serve and protect the periodontium. P. gingivalis can dysregulate this cytokine network 
[384] of that is detrimental and advances the disease progression [233-241]. These 
bacteria induced dysregulation causes the perpetual inflammation that modifies the 
immune response resulting in the chronic pathology seen in PD [213]. Currently, no 
effective treatments are available to regulate the inflammatory responses. The treatment 
regimens available target microbes by local debridement and antimicrobial therapy but do 
not regulate inflammatory responses. Therefore, targeting the underlying mechanism that 
is dysregulation of the homeostatic control between pro-inflammatory and anti-








The IL-1β gene demonstrates variations in multiple ethnicities and influenced the 
severity of chronic periodontitis [385]. In Chapter 2, the stimulation with P.g. LPS 
(1µg/ml), TNFα (10 ng/ml), and IL-1β (1 ng/ml) resulted in increased response of IL-6 
and MCP-1 production and confirmed that in hPDLFs, IL-1β is most sensitive which 
produced the most robust response out of the 3 stimuli tested. Therefore, IL-1β was the 
appropriate stimulus for the studies. Additionally, salivary levels of IL-1β also correlate 
with the severity of PD [278]. Due to this prominent role of IL-1β in inflammation, 
multiple clinical trials have tried to target IL-1β or the pathway involved in the regulation 
of inflammation that would lead to development of a new therapy [386, 387]. To date, no 
efficacious therapies targeting the inflammatory pathways in PD have been developed. 
Our current work with the novel CB2 inverse agonist SMM-189 in hPDLFs, and previous 
work in activated microglia, demonstrated suppression of pro-inflammatory cytokines 
and chemokines [185]. Additionally, SMM-189 as an anti-inflammatory agent is suitable 
for the periodontium that readily contains CB2 receptor [230, 231] located in the 
periodontal tissues and provides an optimal target for therapeutic manipulation. The 
results of this study were intriguing as SMM-189 fulfils the requirement of novel anti-
inflammatory agent to treat chronic inflammation in PD. 
 
 
Overview of Cannabinoids and Our Results 
 
Selective targeting of the CB2 receptor that is found extensively in the peripheral 
system helps avoid the adverse psychotropic effects associated with the CB1 receptor. 
Our lab developed a CB2 inverse agonist, 3',5'-dichloro-2,6-dihydroxy-biphenyl-4-yl)-
phenyl-methanone (SMM-189) [186], which has shown beneficial anti-inflammatory 
effects on several primary cell lines including hPDLFs. In Chapter 2 proof of principle 
was demonstrated that selective CB2 ligands are effective anti-inflammatory agents for 
regulation of periodontal inflammation. It was shown that both agonist and inverse 
agonist were effective in down-regulating P.g. LPS-, IL-1β- and TNF-α-stimulated IL-6 
and MCP-1 levels in primary hPDLFs. Meanwhile, AEA induced a pro-inflammatory 
response in hPDLFs alone, while in hPDLFs activated by P.g. LPS, TNF-α, or IL-1β and 
treated with AEA exhibited anti-inflammatory effects. Thus, a PD model with IL-1β 
stimulated hPDLFs that would mimic the disease condition by creating dysregulated 
inflammation that promotes a pro-inflammatory state was validated. IL-1β is produced by 
activated macrophages [287] and influences severity of the chronic periodontitis [385]. 
Salivary levels of IL-1β correlate with the severity of PD [278], while it can be 
modulated by pathogenic mechanisms to development and/or progression of many 
inflammatory disease states including PD [388]. Studies were conducted to further 
establish parameters for this model of PD. It was observed that the production of pro-
inflammatory cytokines and chemokines, such as IL-1β, IL-6, IL-8, and MCP-1 were all 
upregulated with IL-1β stimulation, markers that are known to affect bone resorption and 
destruction of periodontal tissues [219-223]. Furthermore, in a systemic review, GCF 
levels of cytokines and chemokines IL-1β, IL-6, IFNγ, and MCP-1 were significantly 
higher in chronic PD than periodontally healthy patients. This model also supports the 
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reported activity of periodontal ligamental cells that are known to behave like immune 
cells, possibly due to their proximity to bacterial species within the periodontal pockets 
[377].  
 
The proof of concept studies were expanded to evaluate a spectrum of cytokine, 
chemokines, angiogenic, and leukocyte adhesion proteins that have yet to be examined in 
PD. In these studies it was discovered that all the markers upregulated by IL-1β were 
downregulated by the inverse agonist SMM-189. It was further discovered that even 
though HU-308 exhibited excellent inhibitory effects, it was not as effective in the degree 
of inhibition as SMM-189. Furthermore, HU-308 did not show any suppression of IL-13 
or VCAM-1 as was measured for SMM-189. A paradoxical discovery was that AEA 
significantly decreased IL-1β, IP-10, MCP-1, MDC while increasing IL-6, IL-8, MIP-1α, 
MIP-1β, and VEGF significantly compared to IL-1β alone. AEA appears to have a 
perplexing role in which it has dual activity serving both as a pro-inflammatory and anti-
inflammatory agent.  While there are no direct studies in PD, the effects of AEA may be 
related to pathologies of liver disease. During acute and fatty liver disease, AEA 
concentrations increase due to a decrease in fatty acid amide hydrolase (FAAH), an 
enzyme involved with the breakdown of endocannabinoids. [389]. Interestingly, in these 
conditions, lymphocyte appear to exhibit a bias for Th1 phenotype, that increases 
production of proinflammatory cytokines INF-γ and IL-12 and this in turn causes the 
reduction of FAAH expression. A Th2 phenotype favors increase degradation of AEA by 
increased protein expression of FAAH and cytokines IL-4 and IL-10 [390].  It is known 
that AEA activity inhibits NF-ĸB activation [173] and to prevent excessive inflammation 
by promoting anti-inflammatory responses [230].  Therefore, the effects on AEA 
production by cytokines and chemokines suggests auto-regulation of the ECS and that 
different checkpoints can lead to both up- and downregulation of these proteins. In this 
study, evidence is presented that AEA production in PD may not be sufficient to 
counteract chronic inflammation. The results also suggest that synthetic ligands that are 
not susceptible to metabolic clearance could overcome the liabilities of the endogenous 
ligand.  The pharmacological options to decrease pro-inflammatory activity in PD 
requires a drug that works on both immune cells as well as the hPDLFs. Therefore, 
immunomodulation of immune cells and fibroblast using SMM-189 would not only help 
alleviate symptoms of PD but can also help in other pathologies that show similarity and 
correlation to PD [215-218]. 
 
 
Overview of CB Pathways 
 
The anti-inflammatory effects of CB2 agonists and inverse agonists have been 
reported. The paradoxical pharmacology of agonist and inverse agonist anti-inflammatory 
activity are unclear and need to be further explored. Reports of CB2 selective agonists 
JWH-133, HU308 [134] as well as CB2 selective inverse agonist such as SMM-189[185, 
186], JTE-907, SR144528 [179] exhibit blockade of the inflammatory signals via CB2 
receptor-dependent manner. CB2 receptors regulated ERK1/2, JNK, p38, which are 
involved with the activation of NF-ĸB and activator protein 1 (AP-1) [391, 392]. It has 
been reported that NF-κB and AP-1 exhibit synergistic activities [393-395] and are pro-
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inflammatory in nature.  The downstream inhibition of NF-kB can be seen with both 
agonist and inverse agonist, however, the upstream activity demonstrates opposing 
actions on cAMP accumulation.  Specifically, CB2 agonists decrease cAMP while 
inverse agonist increase it [396].  The effects of inverse agonist on stimulated hPDLF 
may reflect an alternate pathway involving PKA and phosphorylation of CREB resulting 
in anti-inflammatory activity.  This is supported by other studies by our group wherein 
inverse agonist stimulate the production pf pCREB in stimulated microglia.  A deeper 
examination of the mechanisms involved with the anti-inflammatory activity of SMM-
189, and other CB2 inverse agonist, will help uncover links of the pathways involve in 
inhibition of cytokine and chemokine expression in PD. 
 
 
Overview of CB2 Agonist Pathway 
 
In normal conditions CB2 selective agonist JWH-015 in quiescent murine 
microglia [196] promotes the activation of ERK1/2 and JNK but not p38 MAPK. 
However, stimulation of microglia with LPS-induced in combination with JWH-133 
resulted in downregulated ER,K1/2  responses [196]. The selective CB2 agonist HU308 
also exhibited suppression of ERK1/2 and p38 MAPK responses in IL-1β stimulated 
fibroblast like synoviocytes [88]. The responses seen in MAPK pathways can differ 
based on the CB1 and CB2 selectivity and functional activity and the effect appears to be 
cell dependent. Only ERK1/2 has been demonstrated to be a common pathway when 
examined in different cells types. SinceIL-1β activates ERK1/2, JNK, and p38 MAPK 
activity it is logical to infer that. The key checkpoint between interleukin-1 receptor (IL-
1R) and CB2Rs signal via ERK1/2 a pathway. Therefore, the activation of IL-1R and 
CB2R simultaneously would cause interrupted signaling of ERK1/2 by disrupting the 
pool of ERK1/2 available in the system. The parallel activation of the two signaling 
pathways would halt one another leading to a “stalemate” resulting in the blockade of 
ERK1/2 activity leading to inhibition of downstream signaling. In my proposed pathway, 
this is one part of the mechanism that attenuates inflammation, however, other kinase 
activity may compensate allowing inflammation to continue. This may be where the 
prolong effect of agonist occurs and improves the anti-inflammatory activity. CB2 
receptor agonist transiently suppresses cAMP in T-cells but prolong agonist exposure 
increases the level of cAMP [198]. The increase in cAMP was also observed in 
monocytes treated with CB2 agonists.  Specifically, it is reported that PI-3/Akt and 
ERK1/2 signal transduction pathways initially trigger chemotaxis but delayed effects 
inhibiting CCR2 and CCR1 mRNA later occur via a PI-3K/Akt and ERK1/2 signaling 
pathways leading to a reduction in chemotaxis[199]. Hence, the delayed effects result in a 
more profound anti-inflammatory activity that is likely due to the desensitization of the 
receptors.  Because CB2 is constitutively active, desensitization of the receptor could lead 
to increased cellular cAMP levels which in turn activate protein kinase A (PKA). PKA 
can then phosphorylates cAMP response element binding protein (CREB), leading to 
translocation to the nucleus. pCREB activity is involved in cellular maintenance and is 
known for its anti-inflammatory response in immune cells [397] (Figure 6-1). 
Furthermore, the pathway described herein has also been suggested in a review article 





Figure 6-1. Proposed Pathway for Signal Transduction by CB2 Agonist during 
Inflammation in hPDLFs 
 
1.Activation of CB2 receptor. 2. Block (AC), leading to decrease in cAMP. 3. Disruption 
of ERK1/2 leading to sluggish proinflammatory activity. 4. Prolong activation, leading to 
internalization receptor complex and consequently raising cAMP. 5. Activation of the 





Overview of CB2 Inverse Agonist Pathway 
 
CB2 inverse agonists have also been shown to be effective in in vitro 
inflammatory models [177, 178, 186].  They also exhibit in vivo anti-inflammatory 
effects that were comparable to steroid prednisolone and immune suppressant FK506, 
without causing systemic immunosuppression [179]. Based on the mechanism of action, 
it can be speculated that CB2 inverse agonist’s decreases MAPK activity in native and 
inflamed cells. It has been reported that SR144528, a CB2 selective inverse agonist, 
caused the decreases of MAPK activity in non-stimulated conditions [398]. However, it 
can be proposed that during inflammation, the CB2 inverse agonists suppress 
inflammatory pathways via activation of AC, which increases cAMP level that activates 
PKA. This activation would cause the activation of pCREB pathway leading to anti-
inflammatory effects. Another mechanism also involves the PKA pathway that causes the 
blockage of MAPK as seen in SR144528 [398].  PKA could phosphorylate receptor 
tyrosine kinase Csk (c-Src), which phosphorylates and turns off lymphocyte specific 
protein tyrosine kinase (Lck). Lck is also a regulator protein that inhibits the formation of 
cAMP when activated [399]. The activation of the TCR in T-cells, abolishes the 
inhibitory effect of Csk on Lck, allowing the initiation of the TCR-induced signaling 
cascades [400-402] and subsequent activation of the MAPK cascades [403]. The Csk (c-
Src) pathway activity is also implicated in macrophages [404] and fibroblasts [405], 
which plays a role in inflammatory disease.  
 
Early upstream activity of inverse agonist causes the inhibition of transcription 
factors AP- 1, NF-κB, and NFAT that suppresses the release of IL-2 and a variety of 
subsequent immune responses [403, 406]. To elaborate on pharmacological action, the 
functional response of GPCRs is based on the binding states. The inverse agonists binds 
to inactive state of the GPCRs [407] and sequesters Gαi and βϒ proteins in CB receptors. 
In a constitutively active system, the formation of an inverse agonist/CB2/Gαi complex 
will prevent the disassociation of the Gαi. The increase sequestration by inverse agonist 
decreases the availability of Gαi within a cell causing a subsequent loss of the inhibitory 
effect modulated by Gαi on AC.  This disrupts the system of check and balances within a 
cell and now the Gαs stimulatory action by basal activity of other GPCRs is unchecked 
and leads to an increase in cAMP. In theory, the inverse agonist unmasks the constitutive 
activity of other GPCRs, via sequestration of the Gαi pool. It can be postulated that during 
inflammation, the IL-1β induced MAPK activity would get blocked as cAMP increases 
shutting down ERK1/2, JNK, and p38 MAPK activity. Meanwhile, the activation of PKA 
would also lead to p-CREB and CREB binding protein (CBP) to co-activate cAMP 
response element (CRE)  leading to anti-inflammatory response [408, 409]. There is 
also evidence that suggests the proinflammatory responses seen by NF-kB activation are 
directly inhibited by p-CREB pathway by diminishing CBP availability, which is a co-
activator for the binding of the NF-kB complex [408]. The inceptive blocking of NF-kB 
complex by pCREB activation by an inverse agonist leads to the suppression of 
inflammatory responses more efficiently. This is supported by a study with SR144528, a 
selective CB inverse agonist, showing that the Gαi mediated insulin and lysophosphatidic 
acid receptors signal transduction pathway of MAPKs were rendered ineffective. 
However, after a prolong exposure of SR144528, the homeostatic control was normalized 
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and the insulin and lysophosphatidic acid receptors activation of MAPKs occurred via Gαi 
[398]. Therefore, it is my hypothesis that CB2 inverse agonists behave as a reboot switch 
for chronic inflammation by completely shifting the system to an anti-inflammatory state, 
which forces the cell to return to its native state achieving homeostatic control.  
Therefore, CB2 inverse agonist should prove to be better intervention for tackling chronic 





In conclusion, 18 out of 40 cytokines, chemokines, angiogenic, and leukocyte 
adhesion biomarkers analyzed were upregulated by IL-1β in hPDLFs. Both CB2 agonist 
HU-308 and the inverse agonist SMM-189 were effective in down-regulating IL-1β-
stimulated cytokine production in hPDLFs. The data also indicates that AEA exhibits 
pro-inflammatory and anti-inflammatory effects in IL-1β-stimulated hPDLFs. The 
effective inhibition of cytokines, chemokines, angiogenic, and leukocyte adhesion PD 
biomarkers by CB2 ligands demonstrates that targeting the endocannabinoid system may 
lead to the development of novel drugs for treating chronic inflammation in periodontal 
disease. The secondary effects in promoting bone growth and inhibiting bone resorption 
has the potential to yield a novel therapeutic intervention to prevent the devastating 
effects of PD. Furthermore, the studies suggest that distinct anti-inflammatory signaling 
mechanisms occur between CB2 agonist and inverse agonist.  Specifically, inverse 
agonist can trigger the down-regulation of inflammatory responses while promoting anti-
inflammatory pathways. The result suggests that the preferred functional activity at CB2 
is in inverse agonism since CB2 agonists only inhibit the inflammatory component but do 








Figure 6-2. Proposed Pathway for Signal Transduction by CB2 Inverse Agonist 
during Inflammation in hPDLFs 
 
1. Activation of CB2 receptor. 2. Locking of Gαi proteins with the CB2 receptor, 
consequent increase in cAMP. 3. Regulation of Csk/Lck pathway leading to blockade of 
ERK1/2, JNK, p38 MAPK. 4. Activation of the anti-inflammatory pathways by PKA 
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100 µl of each test compound (in duplicate) at three different dilutions were 
incubated with 10 µl of test bacteria (1X105 cells) for 24 hours. At the end of incubation 
period bacterial suspension was centrifuged, the supernatant was discarded. The bacterial 
pellet was re-suspended in 0.1 ml of PBS, to which 20 µl of MTT label (Sigma) was 
added and vortexed to obtain an even suspension. The cells were incubated at 37 C for 2 
hours, and then left overnight with solubilizing agent. The reaction mixture was 
transferred to a 96-well flat bottom micro titer plate and the absorbance was measured at 















Concentration F.nucleatum S. mutans E. fecalis 
0.1 mM 99.4 97.1 100 
1 mM 96.8 89.9 100 
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